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The development of porous materials useful as scaffolds for the sustained three-dimensional 
(3D) growth of human adipose-derived stem cells (hASC) is of particular interest to facilitate 
healing after musculoskeletal injuries.  In this study, a composite porous material obtained by 
blending akermanite with poly-e-caprolactone (PCL) is proposed as novel alternative to bone 
tissue regeneration.  The objectives of this study are (1) to characterize the akermanite:PCL 
scaffold properties; (2) to investigate the in vitro osteogenic potential of hASC loaded to optimal 
akermanite:PCL scaffolds; (3) to assess the metabolic activity and osteogenesis of hASC loaded 
to optimal akermanite:PCL scaffolds after cryopreservation in post-thawed scaffolds; and (4) to 
evaluate the behavior of optimal akermanite:PCL scaffolds in vivo using an immunodeficient 
murine model for ectopic bone formation.  We hypothesized that (1) optimal akermanite:PCL 
blend has mechanical properties and biocompatibility suitable for tissue engineering 
applications; (2) hASC loaded to optimal akermanite:PCL scaffolds has higher expression of 
mature osteogenic marker in scaffolds cultured in osteogenic medium for 21 days; (3) PVP-
serum free medium can be used to cryopreserve hASC loaded to optimal akermanite:PCL 
scaffolds; and (4) hASC preloaded to optimal akermanite:PCL scaffolds would produce 
meaningful bone-like tissue 8 weeks post-implantation.  According to the results, 75:25 
akermanite:PCL composite scaffolds displayed increased mechanical (1), biological and 
osteogenic properties (1-3).  Moreover, hASC loaded to 75:25 akermanite:PCL scaffolds and 
frozen at 40ᵒC/min displayed metabolic activity and osteogenesis comparable to fresh control 
scaffolds (3).  However, in vivo implantation of akermanite-base scaffolds (akermanite and 
akermanite:PCL) led to sudden death within the first 48 hours of this study (4).  The acute 
toxicity observed in all animals assigned to the akermanite scaffolds was associated to a 
xiv 
 
disturbance of the phosphorus homeostasis in vivo.  Specifically, akermanite and 
akermanite:PCL scaffolds harvested 48 hours post-implantation had comparable levels of 
phosphorous in their composition, indicating acute phosphorous depletion from the serum.  
Accumulative evidences have suggested that akermanite is biocompatible and can enhance 
adhesion, proliferation and osteogenic phenotype maintenance of adult/osteoprogenitor stem 
cells both in vitro and in vivo.  As a conclusion, further studies are needed to address the 
akermanite dose-dependent toxicity in murine models for akermanite-assisted bone regeneration. 
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Chapter 1. Human Adipose-Derived Stem Cells and 3D Scaffold Constructs: A Review 
of the Biomaterials and Models Currently Used to Regenerate Bone 
 
1.1. Introduction 
Since the discovery of the human adipose-derived mesenchymal stem cells (hASC) 
osteogenesis
1
, research has substantially progressed toward the use of hASC as stem cell source 
for bone regeneration.  Although some applications would initially involve direct administration 
of stem cells into the target fracture site, current paradigms describing scaffolds loaded with stem 
cells are thought to be preferential in guiding bone regeneration by providing support for cell 
colonization, migration, growth, and differentiation
2
.  During the preceding decade, several cell 
characterization studies have extensively described the differentiation potential and function of 
hACS both in vitro and in vivo along with the benefits of scaffold directed hASC osteogenesis 
(Table 1). 
Perhaps, the most compelling evidence supporting the emerging clinical applications of 
hASC-scaffolds to promote fracture healing in humans was reported in 2004 after a combination 
of autogenous hASC and bone grafts were used to treat an extensive craniofacial injury in a 7-
year-old girl
3
.  In the literature, scaffold-based bone tissue engineering in combination with adult 
stem cells is well established
4-6
, however compiled information regarding scaffold use in 
combination with hASC is still lacking.  Therefore, this review will present a historical 
background on hASC osteogenesis; along with the findings of the current in vitro and in vivo 
hASC-scaffolds models as discussed with emphasis on biomaterial properties; finally, a brief 
discussion on the potential impact of standardization of the current protocols for future hASC-





































































1.2. hASC Osteogenesis: A Retrospective Analysis 
1.2.1. Isolation, Characterization and Problems with Nomenclature 
The term processed lipoaspirate (PLA) cells was first used to describe a subpopulation of 
progenitor cells isolated from human lipoaspirates in 2001
7
.  While the osteogenic potential of 
PLA cells remained elusive in this report, abnormal adipose tissue mineralization was a well-
known pathologic process in several diseases
8
.  Moreover, the embryologic origin of adipose 
tissue offered clues of the presence of a mesenchymal stem cell (MSC) population in PLA cells.  
Confirmation of the multilineage potential of these PLA cells was provided one year later by the 
same group
1
.   
To date, elective subcutaneous liposuction procedures remain the gold standard for human 
adipose tissue collection
1,7
.  The surgical procedure yields anywhere from 300 mL 
to several liters of lipoaspirate
7,9
.  The protocol for isolation of cells from lipoaspirate (or the 
stromal vascular fraction – SVF) was initially described by Rodbell in three consecutive articles 
published in the Journal of Biological Chemistry in 1966
10-12
.  This procedure consisted of 
homogenization of adipose tissue, consecutive saline washes to remove erythrocytes and other 
hematopoietic cells, collagenase digestion, and separation of undigested adipose tissue from the 
pelleted stromal vascular fraction (SVF) containing the ASC.  For human lipoaspirate samples, 
one of the current protocols describes the isolation of 308,849 cells per ml of lipoaspirate
13
.  
Recently, two automated systems were introduced to accelerate SVF isolation (Cellution® 
800/900, Cytori therapeutics; TGI 1000™ cell isolation system, Tissue genesis) but, in general, 
isolation of hASC for scaffold-based applications remains almost identical to the protocols 
originally described (Figure 1).  
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Currently, more than 200,000 elective liposuction procedures are performed annually in the 
United States and over a million worldwide
14
.  Due to ease of harvest and abundance, hASC 
isolated from lipoaspirates are attractive, readily available adult stem cells that have become 
increasingly popular for use in many studies (Table 1). Compared to human bone marrow 
(hBMSC) or umbilical cord stem cells (hUMSC), hASC have similar self-renewal in vitro
15
; and 
the ability of hASC to differentiate in other mesodermal lineages has been demonstrated on 
several occasions
1,7
.  Other studies have indicated that hASC can also be reprogrammed to 




 lineages.  However, despite their apparent 
pluripotential, hASC lack the potential of embryonic stem cell to differentiate into all embryonic 
and extraembryonic tissue types
19
.  Moreover, expression of surface proteins indicated that 
hASC differed phenotypically from hBMSC and hUMSC
20
.  In general, uncommitted hASC 
express the surface markers CD29, CD44, CD71, CD90, CD105/SH2, and SH3 but do not  
express STRO-1 and the hematopoietic markers CD34, CD45 and C117
7,14
.  Even though, great 
strides have been made in the characterization and isolation of pure hASC populations in recent 
years, establishment of homogeneous cultures is still challenging, particularly because of the lack 
of universal hASC markers.  
Since Zuk et al
1
 first reported the PLA cells multipotential, a variety of terms have been used 
to describe the plastic adherent cell population isolated from collagenase digests of lipoaspirates.  
A selection of the most common variations of names can be found in Table 1.  Efforts have been 
made by the regenerative medicine community to refine the nomenclature of multipotent cells 
isolated from adipose tissue.  A consensus was reached at the Second Annual International Fat 






























Figure 1.  Bone tissue engineering paradigm with human adipose-derived 
stem cells (hASC). From hASC isolation and expansion to scaffold loading 




to the non-embryonic subpopulation of cells isolated from bone marrow and periosteum.  The 
Mesenchymal and Tissue Stem Cell Committee (MTSCC) of the International Society for 
Cellular Therapy concluded that there is not enough scientific information available to accurately 
support stemness in plastic-adherent populations of cells
23
.  Therefore, in 2005 the MTSCC 
recommended that the use of the term mesenchymal stem cells should be reserved for population 
of cells with proven self-renewal and multilineage differentiation potentials.  For plastic-adhered 
population of cells that do not meet these criteria, the MTSCC strongly encouraged the 
replacement of the term ‘stem’ in MSC to ‘stromal’
23
.  In agreement with this recommendation, 
the use of the “ASC” acronym to mean “adipose-derived stromal cells” is also accepted. 
1.2.2. Culture Requirements 
Following human adipose tissue digestion, the SVF pellets were initially resuspended in 
control medium (Dulbecco’s modified Eagle’s medium (DMEM), 10% FBS, 1% 
antibiotic/antimycotic solution) and plated at high cell densities
1,2
.  Today, hASC are usually 
maintained in medium containing DMEM/Ham’s F12, 10% FBS, and 1% 
penicillin/streptomycin/amphotericin and often supplemented with epidermal growth factor 
(EGF), fibroblast growth factor (FGF-β) and transforming growth factor (TGF-β)
24
.  
Additionally, protocols also differ in recommendations for cell seeding density.  Evidences 
suggest that high cell densities impair hASC multipotent properties; therefore, low seeding 
density and subconfluent passaging are recommended
14,17,18,24
.  While bovine serum has raised 
awareness to the potential transmission of zoonotic diseases to recipients, hASC culture in 
serum-free medium
25
 or low concentrations of human serum supplemented with FGF-β and EGF 
have also been proposed
 24
.  Standardization of the hASC culture conditions could facilitate 
comparisons between different studies. 
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1.2.3. hASC Osteogenic Differentiation 
Deriving bone from hASC requires a well-defined process wherein hASC differentiate into 
osteoblast precursors (osteoprogenitor, pre-osteoblast), followed by the maturation of osteoblasts 
and the formation and mineralization of a matrix
6




, mRNA expression of 
the osteogenic transcription factor core binding alpha factor 1 (Cbaf-1/RunX2) was first detected 
after 4 days in hASC cultured in osteogenic medium [DMEM, 10% FBS, 0.01 μM 1,25-
dihydroxyvitamin D3 (or 0.1 μM dexamethasone), 50 μM ascorbate-2-phosphate, 10 mM β-
glycerophosphate, and 1% antibiotic/antimycotic].  Up-regulation of Cbaf-1 in hASC starts to 
take place as early as day 1 of culture in osteogenic media preparations
26
 similar to the finding 
originally described
1
.  Current research indicates that the molecular mechanism of MSC 
osteoblastogenesis resembles the mechanism observed during the development of the skeleton, 
where hedgehog
27
, Wnt and BMP
28
 (bone morphogenic protein) signaling pathways play major 
roles.  In particular, costimulation of the Wnt and BMP pathways produces pronounced 
osteogenic differentiation of multipotent cells in vitro
28
.  BMPs stimulate the transcription of 
Cbaf-1 and Osterix (OSX), which in turn activates osteoblast-specific genes such as alkaline 
phosphatase (ALP), osteopontin (OP), osteonectin (ON), bone sialoprotein (BSP), collagen type 
1 (COL1) and osteocalcin (OCN) by binding to the osteoblast-specific cis-acting element 2 
(OSE2) in the promoter region of these genes
28
.  Alkaline phosphatase is an early stage marker 
for osteogenic differentiation, while COL1 and OCN are only expressed by mature osteoblasts
26
.  
As little information is available regarding the downstream regulatory events responsible for the 
commitment of hASC toward the osteogenic pathway, in vivo studies have relied on the ability to 
monitor the expression of one or more of these osteogenic makers in committed hASC during 
formation of functional bone (Table1). 
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Bone remodeling is a process of continuous resorption and neosynthesis that determines bone 
structure and quality during adult life.  Bone formation and bone resorption are coupled 
processes.  For instance, mature osteoblasts can modulate osteoclast formation by expressing the 
negative regulator osteoprotegrin (OPG) or the positive regulator RANKL (receptor activator of 
NFB ligand)
29
.  Imbalances of bone remodeling can result in severe perturbations in skeletal 
structure and function.  For example, osteoporosis results in reduction of bone density in aged 
people. The disease affects millions worldwide and individuals living with osteoporosis are more 
at risk of fracture
14
.  As hormonal differences are observed between gender and within age 
groups, hASC osteogenesis is, therefore, predicted to be affected by deficiency or decreased 
levels of gender steroids
8,30,31





 BMP-2 controlled delivery systems can enhance the osteogenic potential of hASC 
isolated from individuals within different age groups, this suggesting that hASC-scaffolds in 
conjunction with diffusible factors have the potential to become an alternative fracture repair 
treatment for patients suffering from osteoporosis in the future.  
In the past decade, substantial research has been conducted in an effort to better understand 
the osteogenic fate of the PLA cells isolated in 2001
7
.  Human lipoaspirates are readily obtained; 
the stem cells present in the SVF have great self-renewal potential and have been demonstrated 
to differentiate into cells of all embryonic germ layers.  Even though much of the molecular 
characterization still remains to be conducted, the expression of known osteogenic markers has 
been used successfully to monitor hASC osteogenesis (Table 1).  Human ASC cultured in 





 growth factor supplementation paving the way for the potential use of hASC-scaffold 
combinations to treat different diseases. 
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1.3. hASC and Scaffolds for Bone Tissue Engineering 
1.3.1. The Tissue Engineering Decade 
Bone tissue engineering has been heralded as the alternative strategy of the twenty-first 
century to replace or restore the function of traumatized, damaged, or lost bone 
35,36
.  Over the 
years, bone grafts have advanced as the gold standard treatment to augment or accelerate bone 
regeneration.  Autogenous cancellous bone grafts have long been used to facilitate bone healing
35
 
though quantity is limited and surgical procedures for graft harvest are required.  Allogeneic 
bone grafts are costly, require time-consuming bone banking procedures and have the potential 
for disease transmission
35
.  A current research paradigm of bone tissue engineering utilizes 
hASC isolated after elective lipoaspiration, in vitro population expansion and in vivo delivery 
within a scaffold or matrix
2,5,6,37
 in a configuration that generates new functional bone (Figure 2).  
Scaffold-induced hASC osteogenesis has been demonstrated experimentally in a variety of tissue  
engineering strategies (Table 1).  Compared to allogeneic grafts, the risk of donor pathogen 
transfer to recipients is minimal
37





lack of T cell priming
38
 make hASC an attractive alternative to traditional bone grafting 
techniques.  
At present, tissue engineering studies combined with hASC can generally be divided into two 
categories.  These include the in vitro characterization of the hASC osteogenic potential in novel 
or commercially available scaffolds and in vivo studies performed in either rats or mice models 
for calvarial bone defects or subcutaneous ectopic bone formation (Table 1).  Several studies 







generation of synthetic polymers
38,42-45
 or ceramic scaffolds
26,30,34,39,40,46-50





generations of bioabsorbable scaffolds
15,30,32,33,49,51-54






















Figure 2.  Potential clinical orthopedic applications for the use of bone-substitute scaffolds: (a) 
calvarial defects, (b) anterior spine fusion, (c) acetabular defects after hip replacement/revision 
surgery, (d) cystic lesion femur condyle metaphysis, (e) ankle joint arthrodesis, (f) 
osteolytic/traumatic long bone defects and (g) iliac defects.  Adapted from Reichert & 
Hutmacher
35 








While current scaffold materials facilitate the attachment of hASC by providing an 
interconnected pore structure to support cell migration, proliferation, differentiation
2
 and in some 
cases formation of blood vessels
40,47
, the major limitations of the 1
st
 generation of bioabsorbable 
scaffolds used today are their relatively poor mechanical properties and brittle behavior
35,36
.  The 
latest innovation for bioactive and fiber-reinforced biomaterials, is to use both 
bioactive/bioabsorbable ceramics and bioabsorbable polymeric fiber reinforcement in the same 




 generations of bioabsorbable scaffolds)
35,36
.  
Composite ceramics/polymers are being explored as an alternative to address the mechanical 
limitations of 1st generation ceramics
35
.  The polymer phase allows for tunable rheological 
properties while the ceramic phase contributes to osteoinduction and osteoconduction.  To date, a 
clear trend towards the use of composite scaffolds can already be observed in some of the current 
models
15,30,32,33,49,51-54




 generation composites will 
be preferred as scaffolding materials for hASC in future clinical trials
24
.  
1.3.2. Current Biomaterials Used in hASC Bone Tissue Engineering Strategies  
 Biological Materials 
Extracellular matrix (ECM) molecules are naturally occurring materials that have been 
commonly used as tissue engineering scaffolds combined with hASC 
39-41
.  Decellularized 
xenogeneic ECM is well tolerated by human hosts as components of the ECM are generally well 
conserved among species which may contribute to reduced rates of rejection and associated 
complications.  Among the different xenografts commercially available, deproteinized bovine 
bone granules (Bio-Oss®) were recently investigated as a substrate for hASC osteogenesis in 
vitro
39
 and in an ectopic bone formation model using immunodeficient (nude) mice
40
.  Bio-Oss® 
is a highly porous inorganic material composed of calcium deficient carbonate apatite that was 
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observed to produce bone after hASC loading both in vitro
39
 and in vivo
40
.  In addition to 
deproteinized grafts, the in vitro osteogenic potential of decellularized bovine loaded with hASC 
after perfusion bioreactor has been demonstrated
 41
.  The decellularization step is critical process 
in ECM isolation as xenogeneic and allogeneic cellular antigens can trigger an inflammatory 
response and/or tissue rejection.   
ECM scaffolds are often combined with site specific cells, usually autologous cells from the 
intended recipient before utilization for tissue repair
3
.  The requirement for cells to promote a 
constructive remodeling response scaffold varies.  For bone applications, current models directly 
load hASC on bone grafts in the presence or absence
39
 of a perfusion system
41
.  In another 
approach, hASC were initially loaded on a fibrin hydrogel and then the hASC-fibrin hydrogel 
was wrapped around an orthopaedic construct
40
.  To date, the bone formation potential of hASC 
combined with ECM scaffolds has been evaluated in vivo under non-weight bearing conditions 
(Table 1).  Unmodified ECM scaffolds degrade over time via enzymatic degradation and 
hydrolysis, changing the strength and mechanical properties of the scaffold after implantation
36
.  
Therefore, the understanding of the biomechanical properties of the ECM loaded with hASC in 
weight bearing situations will be critical to future clinical use.   
 Natural Polymers  
Natural polymers were the first to be used in hASC-scaffold studies because they are either 
components of, or have properties similar to, the natural ECM
3,32,33,45
.  For bone tissue 
engineering applications in combination with hASC, natural polymers are often derived from 






 have been demonstrated to interact 
favorably with hASC through specific recognition domains present in their structures.  
Additionally, these protein-based polymers can be degraded by naturally occurring enzymes, 
13 
 
allowing them to be modified, degraded and absorbed in vivo
36
.  Often when used in scaffolding 
materials natural polymers can result in a construct with superior mechanical and biological 
properties
36
.   
Currently, 19 different types of collagen have been described, with the most abundant being 
type 1 collagen
36
.  Collagen is composed of three polypeptide chains that intertwine with one 
another to form a triple helix.  The polypeptide chains have a repeating sequence of glycine-X-Y, 
where X and Y are most often found to be proline and hydroxyproline and the chains are held 
together through hydrogen bounds.  Collagen is enzymatically biodegradable, and has a tendency 
to degrade rapidly in vivo, reducing mechanical strength (Table 2).   
Fibrin is a fibrous protein naturally produced in the body and that plays a crucial role in 
wound healing and blood coagulation
8
.  It is TGF-β-rich and has been used to augment hASC 
attachment to scaffold materials
3,33,40
.  Fibrin polymerization relies on thrombin to convert 
fibrinogen into fibrin.  Once a gel is formed, studies describe the use of hASC-fibrin composites 
as a coating for more mechanically robust scaffold constructs
33,40
.   
Gelatin is a collagen derivative acquired by denaturing the triple-helix structure of collagen 
into single-strand molecules.  It is water-soluble, and entangles easily to form into a gel through 
changes in temperature and is readily broken down enzymatically by various collagenases.  The 
most commonly described form of a gelatin scaffold is a hydrogel and in this form
 
it has been 
used to support hASC growth and osteogenic differentiation
32
. 
The use of collagen, fibrin and gelatin for hASC osteogenesis has been successfully 
demonstrated.  However, collagen in bone engineering application should be used to promote 
































































































mechanical strength and are susceptible to fast enzymatic degradation which can, therefore, 
result in unpredictable in vivo mechanical properties. 
 Synthetic Polymers 
A variety of biocompatible synthetic polymers are commercially available enabling the 
design of scaffolds with specific mechanical and biological properties and controllable 
degradation rates.  These polymers can be produced reproducibly in highly purified forms and 
can be easily processed into devices by casting, extrusion, molding or coating.  Much of the 
research utilizing synthetic polymers in hASC-combined tissue engineering has been focused on 
hybrid cell/scaffold constructs using degradable polyester polymers such as PLGA
42,43,51,53
 which 












 have been shown to 
support hASC proliferation and differentiation (Table 1).  The clear advantage of synthetic 
polymers is that they are highly pure, readily reproducible and have flexible mechanical, 
chemical and biological properties allowing them to be tailored to suit specific functions.  A 
significant disadvantage of using synthetic polymers is that some, such as PLGA and PLLA, 
degrade into non-biocompatible products, often acids which can perturb the scaffold 
microenvironment leading to cell dysfunction or death.  At high concentrations of these 
degradation products, local tissue acidity may increase, resulting in adverse responses such as 
inflammation or fibrous encapsulation
36
.  
One of the most frequently cited synthetics for bone scaffolds is poly(l-lactic acid-co-glycolic 
acid –PLGA).  PLGA is the result of the copolymerization of PLLA and PGA.  This copolymer 
is amorphous, and has a decreased degradation rate and mechanical strength compared to PLLA 
16 
 
(Table 2).  PLGA typically undergoes bulk degradation by self-catalyzed ester hydrolysis
36
.  The 
degradation rate of PLGA can be controlled by adjusting the ratio of PLLA/PGA in the solution.  
For example, a 50:50% ratio of PGA and PLLA typically degrades faster than either 
homopolymers.  PLGA has been used alone as a scaffold
 42,43





 to repair calvarial bone defects in rats
43
 or nude mice
51
 as well as to 
investigate ectopic bone formation in nude mice
42,53
.   
Poly(l-lactic acid) (PLLA) is one of two isomeric forms of poly(lactic acid):D and L.  Similar 
to PGA, PLLA is classified as a linear poly(alpha-hydroxy acid) that is formed by ring-opening 
polymerization of L-lactide.  PLLA is structurally similar to PGA, with the addition of a pendant 
methyl group
36
.  This group increases the hydrophobicity and reduces the melting temperature to 
170
o
-180ᵒC.  PLLA typically undergoes bulk, hydrolytic ester-linkage degradation, but 
decomposes into lactic acid
36
.  The additional pendant methyl group hinders the ester bond 
cleavage of PLLA, resulting in a decreased hydrolytic degradation rate and greater in vivo 
mechanical stability (Table 2).  In recent investigations, PLLA has been blended with β-
tricalcium phosphate (β-TCP)
49,52
 and bioactive glass
49
 to assess the in vitro osteogenic potential 
of hASC in novel biodegradable scaffolds and these results have shown that PLLA-composites 
can induce osteogenic differentiation of hASC in vitro.  
Poly(e-caprolactone) is a aliphatic polyester with semi-crystalline properties
36
.  PCL is 
formed through ring-opening polymerization and has repeating units of one ester group and five 
methylene groups.  It is poorly water-soluble with a melting temperature of 58 to 63ᵒC.  The 
degradation of PCL occurs by bulk or surface hydrolysis of ester linkages resulting in a 
byproduct of caproic acid
38
.  PCL degrades slowly in physiological conditions and it can persist 
in vivo for up to 2 years
36









 in an effort to increase the degradation rate of the scaffolds.  The 
ease with which PCL can be copolymerized with a variety of polymers has made it an attractive 





composites blended with β-TCP are also available and they have been shown to produce bone 
after hASC loading in ectopic bone formation models using nude mice
15,54
. 
Poly(ethylene glycol) (PEG) is a linear-chained polymer consisted of an ethylene oxide 
repeating units.  Poly(ethylene oxide) PEO has the same backbone as PEG, but a longer chain 
length and thus a higher molecular weight
36
.  PEG is hydrophilic and synthesized by 
anionic/cationic polymerization.  The ability of PEG to swell in aqueous solution has led to its 
use as a hydrogel, and in some instances as an injectable hydrogel
38,44
.  Unfortunately, the linear 
chain form of PEG leads to rapid diffusion and low mechanical stability (Table 2).  Crosslinked 
PEG networks may be created by attaching functional groups to the ends of the PEG chain and 
then initiating covalent cross-linking by chemical, thermal or photoactiviation
36
.  PEG is resistant 
to degradation, however, rates of degradation may be increased by copolymerization with 
hydrolytically or enzymatically degradable polymers
38,44
.  The flexibility of PEG modification, 
whether with cross-linkable groups for network formation or degradable groups for absorbable 
applications, has led to the interest in PEG for hASC based bone tissue engineering.  For 




 to form a gel which after 
hASC loading has been demonstrated to produce ectopic bone in rats
38




Polyurethane (PUV) is an elastomeric polymer that is typically nondegradable
36
.  Positive 
attributes, such as tailorable mechanical strength and biocompatibility have led to the synthesis 
of degradable polyurethanes with nontoxic diisocyanate derivatives
36 
(Table 2).  However in 
18 
 
bone tissue engineering applications combined with hASC, PUV has been used only as a 
template during the fabrication of β-TCP
 
and akermanite scaffold discs
26
 which were used to 
investigate the osteogenic potential of hASC in vitro. 
 Bioceramics 
Bone is composed of HA crystals distributed within an organic matrix with porosity and 
percent mineralization varying among bone types
35
.  It is generally agreed that ceramic 
biomaterials used in bone tissue engineering applications should mimic, as closely as possible, 
the natural bone architecture to ensure cell attachment and migration within the porous materials.  
Additionally, they should be absorbed overtime or integrated with the surrounding tissue and 
eventually be replaced by new or existing host tissue
36
.  The concept of bioactivity originated 
with bioactive glasses by the hypothesis that the biocompatibility of an implant is optimal if it 
elicits the formation of normal tissues at its surface while establishing a contiguous interface 
capable of supporting the loads which occur at the site of implantation
35,36
.  Bioceramics used in 














, Titanium (Tabrecular Titanium®)
39,46
; polymeric 





Several calcium-phosphate ceramics with varying calcium-to-phosphate ratios have been 
explored for bone regeneration.  Among the Ca-P materials, the apatites are the most commonly 
studied for osteogenesis due to their chemical and crystalographic similarities to native bone.  
Apatites form a range of solid solutions as a result of ion substitution
35,36
 .  The most common 
apatite used in bone tissue engineering applications is HA
30,39,40,47,51,53
.  Studies have shown that 
hASC seeded on HA form ectopic bone in nude mice
40,47,53
, but the inability to attract new 
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osteoprogenitor cells or cytokines (osteoinduction) to the site of implantation make HA a non-
ideal choice for bone tissue engineering strategies
26,35,36
. 
Synthetic apatites are processed via hydrolysis, hydrothermal synthesis and exchange, sol-gel 
techniques, wet chemistry, and conversion of natural bone and coral
35,36
.  Differences in the 
structure, chemistry, and composition of apatites arise from differences in processing techniques, 
time, temperature, and atmosphere.  β-tricalcium phosphate, is a synthetic apatite with 
osteoconductive and osteoinductive properties superior to HA and it has been combined with 
hASC in several studies
15,32,34,40,49,52,54
.  More recently, Liu et al.
 
compared the osteogenic 
potential of hASC loaded in β-TCP and akermanite scaffolds
26
.  According to this study, 
increased expression of osteogenic markers were observed in akermanite scaffolds compared to 
β-TCP, loaded with hASC after 10 days.  Akermanite (Ca2MgSi2O7) is believed to have a stable 
degradation rate and superior bone deposition compared to β-TCP constructs (Table 2).  
Moreover, akermanite scaffolds may enhance recruitment and osteogenic commitment of hASC 
due to the cells affinity for Ca, Mg, and Si ions in the scaffold
26
, but, to date, both, akermanite 
and β-TCP, are still being evaluated as options for bioceramic bone matrices. 
Scaffold technology is playing an important role in the success of the current bone tissue 
engineering strategies.  Several different materials have been tested in combination with hASC, 
but as noted by Lendeckel et al., composite scaffolds may offer a better clinical outcome in terms 
of mechanical and biological properties
3
. 
1.3.3. Current Bone Tissue Engineering Models: A Retrospective Analysis on hASC-
Scaffolds 
 
Over the past several years, a wide range of bone grafts and synthetic materials became 
available for scaffold-assisted bone regeneration (Table 1).  When considering the current studies 
for bone applications with hASC, cell cultures and animal models are the most common.  Even 
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though Lendenckel et al. demonstrated that hASC can be clinically used to promote calvarial 
healing in humans
3
, obvious ethical and safety concerns prevent human testing as the first stage 
in novel scaffold development
35
.  Among the animal models available today, inserting 
biomaterials subcutaneously in rats
38
 and nude mice
15,38,40,42,45,47,53,54
 are the most common.  
Calvarial defect models have also been described for the same species
43,44,51
.  They can be used 
to provide first phase (non-load bearing) bone healing models with relative biological inertness 
due to poor blood supply and limited bone marrow exposure
35
.   
The first study comparing the in vivo osteogenic potential of hASC (referred as human 
adipose tissue stem cells or ATSCs) with hBMSC in scaffolds was performed by Hattori et al
45
.  
After both cell types were seeded on to water soluble collagen honeycomb-shaped scaffolds they 
were subcutaneously implanted in nude mice.  Ectopic bone formation was assessed 4 weeks 
later in both animal cohorts.  According to the results, osteogenic differentiation of ATSCs on 
scaffolds was similar to that observed in scaffolds loaded with hBMSC after 4 weeks.  Two years 
later, in 2006
54
, Jeon et al. investigated the in vivo osteogenic potential of hASC (human 
adipose-derived precursor cells - ADPC) seeded on β-TCP-PCL composites in a rat model.  
Experimental groups included: induced—stimulated with osteogenic factors only after seeding 
into scaffold; preinduced—induced for 2 weeks before seeding into scaffolds; and uninduced 
cells. Results 12 weeks post-implantation indicated comparable expression levels of osteogenic 
markers in scaffolds loaded with induced and preinduced groups and both groups had 
significantly higher marker levels than uninduced controls.  In the following year, Scherberich et 
al. utilized the same composite (β-TCP-PCL) to load SVF cells using a perfusion system
47
.  After 
loading, SVF-scaffolds were subcutaneously implanted in nude mice to investigate if SVF could 
differentiate toward the osteogenic and angiogenic pathways.  Twelve weeks post-implantation, 
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calcified constructs contained blood vessels functionally connected to the host vasculature.  In 
summary, these first studies demonstrated that hASC loaded to scaffolds have osteogenic 
potential similar to hBMSC and, besides bone, SVF loaded to scaffolds can also form blood 
vessels. 
Several studies focused on the in vitro characterization of the hASC osteogenic potential in 
novel
26
 and commercial scaffolds
33,39
 as well as calvarial repair and ectopic bone formation in 
nude mice
44,53
 were performed in 2008.  The first calvarial bone defect model for hASC-scaffold 
osteogenesis was proposed by Degano et al.
44
.  In this study, luciferase labeled hASC (human 
adipose tissue MSC - hAMSCs) and hBMSC loaded to PEG-RGSD, peptide functionalized, 
scaffolds were implanted in calvarial defects of nude mice and were monitored for 12 weeks.  
According to these results, hBMSC had better survival rates than hAMSCs, but bone density in 
calvarial defects bearing scaffolds loaded with both cell types increased significantly more than 
that of defects without scaffolds.   
Liu et al. compared the potential for in vitro osteogenesis of hASC on akermanite and β-TCP 
scaffolds for up to 10 days
26
.  Fresh human lipoaspirates were obtained from three healthy 
patients (mean age, 32 years) after elective liposuction procedure.  Passage 3 of each individual 









 (for osteogenic differentiation assays).  
Nonseeded discs were similarly treated as blank controls.  Density of cells attached to 
akermanite and β-TCP scaffolds significantly increased after seeding with no significant 
differences between both scaffold types.  Likewise, live/dead staining and lactate dehydrogenase 
(LDH) release assay indicated that the observed cytotoxicity did not significantly impact cell 
viability on both akermanite and β-TCP scaffold surfaces.  Expression of ALP, OCN and COL1 
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increased overtime in hASC seeded on both scaffold types and cultured in either control or 
osteogenic media.  Differences between scaffolds were observed only after 10 days of culture, 
where expression of the osteogenic markers was significantly higher in akermanite scaffolds. 
According to the authors, the in vitro osteoinductive bioactivity of akermantie scaffolds indicated 
that the material could be used to support bone regeneration.   
Another in vitro study performed in 2008 characterized the in vitro osteogenic potential of 
hASC isolated from twenty-three donors in both 2D and 3D cultures
39
.  The findings indicated 
that HA (Engipore®), cancellous human bone fragments, deproteinized bovine bone granules 
(Bio-Oss®), and titanium (Trabecular Titanium®) scaffolds could support the growth of pre-
differentiated hASC.  Human bone fragments and bovine bone granules were able to induce 
osteogenic differentiation of control and osteogenic differentiated hASC on 3D scaffolds to a 
greater extent than in observed in hASC cultured on 2D monolayers. .  The authors concluded 
that further in vivo studies are needed to confirm the findings, but the data suggested that culture 
on 3D scaffolds increases the osteogenic potential of hASC compared to planar culture.  In 
addition to these two in vitro studies, Leong et al. detailed an in vitro study using mPCL-TCP 
(Osteopore®) in three-dimensional (3D) tissue culture systems
33
.  hASC (or human adipose-
derived stem cells – ADSCs) from 3 donors were seeded onto scaffolds treated with fibrin glue 
and lyophilized collagen.  ADSCs within these scaffolds were then induced to differentiate along 
the osteogenic lineage for 28 days to compare the adhesion, viability, proliferation, metabolism 
and differentiation as a function of scaffold composition and culture condition.  The ADSCs cells 
were proliferative in both collagen and fibrin mPCL-TCP scaffold systems with a consistently 
higher cell number in the induced group over the non-induced groups for both scaffold systems.  
In response to osteogenic induction, these ADSCs expressed elevated OCN, ALP and ON levels 
23 
 
compared to the non-induced groups. Cells were able to proliferate within the pores of the 
scaffolds and form dense cellular networks after 28 days of culture and induction. The authors 
concluded that the successful cultivation of osteogenic ADSCs within a 3D matrix comprising 
fibrin glue or collagen, immobilized within a robust synthetic scaffold is a promising bone tissue 
engineering technique.   
Finally, the first composite scaffolds incorporated with a control-released BMP-2 were also 
tested in 2008
53
. Jeon et al 2008 fabricated a HA-PLGA incorporated with BMP-2 to investigate 
the in vitro and the in vivo osteogenesis of hASC (human adipose-derived stem cells - hADSCs).  
In vitro analysis indicated that hADSCs cultured on BMP-2-loaded HA-PLGA scaffolds for 2 
weeks expressed the osteogenic markers ALP, OP, and ON mRNA, while cells on HA-PLGA 
scaffolds without BMP-2 expressed only ALP.  Human ADSCs ectopic bone formation 
associated with control-released BMP-2-HA-PLGA scaffolds was also investigated 8 weeks after 
subcutaneous implantation in nude mice.  Cohorts included four groups:  HA-PLGA scaffolds 
only, BMP-2-loaded HA-PLGA scaffolds, undifferentiated ADSCs seeded on HA-PLGA 
scaffolds, and undifferentiated ADSCs seeded on BMP-2-loaded HA-PLGA scaffolds.  Eight 
weeks post-implantation, ASCs loaded to BMP-2-HA-PLGA scaffolds exhibited greater bone 
formation area and calcium deposition than ASCs loaded to HA-PLGA scaffolds. The authors 
concluded that HA-PLGA composites integrated with a BMP-2 delivery system can enhance the 
in vitro and in vivo osteogenic differentiation of hASC without prior in vitro exposure to 
osteogenic media supplements.  As a conclusion, the studies performed in 2008 indicated that 
scaffolds can be used to monitor local in vivo hASC viability and differentiation.  Moreover, 
several in vitro studies tested hASC osteogenesis in varying scaffolds often enhanced with 
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adhesion molecules.  Finally, Jeon et al 2008 demonstrated for the first time that BMP-2 can be 
incorporated to scaffolds to promote controlled osteogenesis of hASC in vivo.  
Characterization of novel scaffolds for hASC osteogenesis was the major topic for the studies 
performed in 2009.  Girolame et al 2009
 
described changes in the hASC-scaffold osteogenesis 
between females of different age groups
30
.  This study compared the in vitro osteogenic potential 
of hASC isolated from 26 adult female donors in both monolayer cultures and HA or silicon 
carbide (SiC-PECVD) scaffolds.  The cellular yield of hASC from older donors was significantly 
greater than that observed from younger donors; however reduced osteogenesis correlated 
significantly with aging in both monolayer and 3D scaffold culture.  Of the scaffolds examined, 
hASC osteogenesis was up-regulated in the presence of HA, whereas SiC-PECVD produced no 
significant effect.  The authors concluded that in females, age influenced the osteogenic 
differentiation of hASC in 2D cultures and in 3D scaffolds.   
The influence of donor cell origin in scaffolds was evaluated by Zhang et al.
15
.  In this study, 
the authors compared the in vitro and in vivo osteogenic potential of four types of MSC loaded 
on β-TCP-PCL scaffolds to investigate if the ontological and anatomical origins of MSC 
influenced ectopic bone formation.  Fetal femurs were collected for isolation of human fetal bone 
marrow (hfMSCs, n =5) after clinically indicated termination of pregnancy; umbilical cords were 
collected for isolation of human umbilical cord MSC (hUC-MSCs) following term deliveries (n 
=3); adipocyte-derived MSCs (hATMSCs) were derived from adipose tissue harvested during 
elective cosmetic surgery (mean age, 41 years, n = 3); and human adult bone marrow (haMSCs) 
samples were collected from 3 donors (mean age, 25 years).  Donor cells were suspended in 
fibrin glue before seeding into the porous 5mm x 4mm scaffolds (1.6X10
5
 cells/scaffold).  
Culture was maintained in osteogenic medium for 28 days.  Samples for DNA quantification and 
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expression of mRNA levels of osteogenic markers were collected in different time points.  MSC 
were seeded onto mPCL-TCP scaffolds and cultured for 2 weeks in osteogenic medium followed 
by subcutaneous implantation in nude mice.  The effect of donor cells on ectopic bone formation 
was evaluated in histological and µ-CT analysis 8 weeks post-implantation.  After 28 days in 
culture, hfMSCs consistently showed a higher DNA content in scaffolds, followed by 
hATMSCs, hUCMSC and haMSC.  Expression of osteogenic markers (ALP, RunX2, COL1A1, 
and ON) and von Kossa staining were also significantly higher in hfMSCs, however, scaffolds 
loaded with haMSCs demonstrated earlier expression of ON, higher expression of ALP and 
higher calcium deposition than scaffolds loaded with hUCMSCs and hATMSCs, respectively.  
Ectopic bone formation in immunodeficient mice 8 weeks after implantation corroborated these 
findings.  Von Kossa staining demonstrated that hfMSCs scaffolds had the largest mineralization 
area and volume, followed by haMSCs scaffolds, hUCMSCs and hATMSCs indicating that the 
in vitro and in vivo osteogenic potential of cells loaded to mPCL-TCP scaffolds is influenced by 
the donor cells origin. 
In the same year, three consecutive in vitro studies, investigated the hASC osteogenic 




, alone or in composites blended 
with PLLA
49
.  In the first study, Haimi et al. evaluated the in vitro effect of two different Ca-P 
treatments of 3D bioactive glass scaffolds on hASC attachment, growth, and osteogenic 
differentiation
48
.  Cells were isolated from adipose tissue samples collected from 10 donors 
(mean age, 48 years).  Passages 3-6 isolated from 2-4 individuals were pooled together and 
seeded on 14 mmX14mmX5mm scaffolds at density of 5X10
5
 cells/scaffold.  After a 3 hour 
initial incubation, the cell-seeded scaffolds were transferred to long term culture for 2 weeks in 
control medium.  Experimental groups included three types of bioactive glass scaffolds: non-
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treated, thick and thin Ca-P treated.  After 2 weeks, no significant differences in the cell 
proliferation, distribution and alkaline phosphatase activity were observed in all three scaffolds.  
However, within the same time point, OP expression in thin Ca-P-treated scaffolds was 
significantly higher than the other two scaffold types.  The authors concluded that the 
osteoconductive and osteostimulative properties of bioactive glass scaffolds should be further 
considered.   
In the following paper, Haimi et al. incorporated different concentrations of zinc into porous 
bioactive glass to evaluate the proliferation and osteogenesis of hASC in these scaffolds
50
.  
Human ASC were isolated, pooled (3-4 individuals) and seeded at the same density on porous 
scaffolds as in the previous study.  Experimental groups included: BG (control), BG+0.25% 
zing, BG+1% zinc.  In general, after 2 weeks no significant differences in cell viability, 
proliferation and osteogenic differentiation were observed between experimental groups.  
However, the ALP activity as well as the DNA content of hASC was significantly increased at 2 
weeks compared to that at 1 week in control scaffolds.  In summary, this study revealed that zinc 
had no effect on the proliferation and osteogenesis of hASC.  The authors concluded that further 
investigations are needed to assess the zinc stimulatory potential to hASC as the addition of zinc 
inhibited the degradation of bioactive glass scaffolds.   
Finally, in the last paper, Haimi et al. also compared the in vitro osteogenic potential of 
human ASC loaded into bioactive glass [BG] and β-TCP scaffolds incorporated with PLLA
49
.  
The hASC were isolated from adipose tissue samples collected after elective liposuction 
procedure in six donors (mean age, 45 years).  Passages 4-7 of different donors (n = 3) were 
pooled together and seeded on the porous surface of 15mmX3mm scaffold constructs at density 
of 3.5X10
5
 cells/scaffold and cultured for 2 weeks in control medium.  Experimental groups and 
27 
 
controls included: 100% PLLA, β-TCP 10%, β-TCP 20%, BG 10%, and BG 20%.  DNA and 
ALP analysis indicated that after 2 weeks cell number and expression of osteogenic 
differentiation markers were comparable in all β-TCP-PLLA scaffolds but were significantly 
higher than the other three scaffold types.  As a conclusion, this study raised promises of the use 
of β-TCP-PLLA composites in bone tissue engineering applications combined with hASC.   
Similarly, McCullen et al. also indicated that β-TCP-PLLA composites might directly 
stimulate the osteogenic differentiation of hASC
52
.  In this study, the electrospun composite β-
TCP-PLLA was evaluated in vitro for viability, proliferation and osteogenic differentiation of 
hASCs after 18 days.  Human adipose-derived adult stem cells (hASC) were isolated after 





 on 10mmX10mm scaffolds composed of varying loading of β-TCP 
crystals and PLLA.  After overnight incubation, cell-seeded scaffolds were maintained in 
osteogenic-differentiating medium for 18 days, scaffolds with no cells served as experimental 
controls.  Overall, high β-TCP concentration weakened the tensile strength of the scaffolds but 
did not affect their stiffness.  In vitro studies demonstrated that electrospun PLLA w/10% TCP 
increases hASC proliferation, while electrospun PLLA w/20% TCP accelerates osteogenic 
differentiation and increases calcium accretion by hASC, compared to neat electrospun PLLA 
scaffolds.  In summary, the conclusion of these four papers together, suggested that bioactive 
glass might be a viable candidate for promoting osteogenesis in bone tissue engineering 
applications when combined with hASC, however compared to β-TCP it has a much lower 
osteogenic potential.  
Within the same year, Ahn et al. evaluated the in vitro and in vivo biocompatibility and 
osteogenic potential of human adipose tissue–derived stem cells (hADSCs) used in conjunction 
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with an injectable mPEG-PCL diblock copolymer
38
.  Human ADSCs were isolated after 
collection of subcutaneous adipose tissue of a female donor.  For the in vitro study, 3X10
4
 cells 
were seeded on gels composed of mPEG-PCL diblock copolymer (20 wt%).  For comparison, an 
equivalent number of hADSCs was seeded on 24-well plates and maintained in culture for 1 
week.  For the in vivo study, experimental groups included: G (gel only), GF (gel+osteogenic 
factor), GC (gel+2X10
5
 hADSCs), and GCF (gel+2X10
5
 hADSCs+osteogenic factor).  Gels 
containing each experimental group were subcutaneously injected in Fisher rats (4 groups of 3 
rats each) and ectopic bone formation was observed 2-4 weeks post-injection.  After 7 days in 
culture, viability of plated cells was higher than in gels composed of mPEG-PCL.  Moreover, 
within this time point, most hADSCs seemed to be located inside the gels rather than surface 
associated.  After 4 weeks, von Kossa staining revealed increased mineralization in gel implants 
containing both hADSCs and osteogenic factors compared to controls.  Inflammation associated 
with host macrophages co-localization was attributed to gel-specific graft rejection of the mPEG-
PCL copolymer gel only, whereas the inflammatory response of gels embedded with hADSCs 
were much reduced.  
In conclusion, studies performed in 2009, indicated that the osteogenic potential of hASC is 
lower compared to hfMSCs in scaffolds and is also significantly affected by donor age. 
Moreover, hASC have better differentiation on composite scaffolds than 1
st
 generation ceramic 
scaffolds. 
Studies conducted in 2010 evaluated the in vitro hASC osteogenesis in custom-made 
xenografts
40,41
, PLGA scaffolds alone
43
 or blended with apatite
51
 as well as 1
st
 generation 






.  Gastaldi et al. 
investigated the in vitro osteogenic potential of hASC loaded on 12mm x 6mm trabecular 
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.  Passage 3 of freshly isolated hASC harvested 
from healthy patients undergoing orthopedic surgery were seeded at density of 1X10
6
 
cells/scaffold and cultured in osteogenic or control medium for 28 days with data collected at 
different time points.  Expression of the osteogenic markers ALP, COL1, OCN and OP as well 
as calcium deposition were higher in scaffolds cultured in osteogenic medium than in scaffolds 
cultured in control medium.  The highest ALP and COL1 expression were observed in scaffolds 
cultured in osteogenic medium after 21 days, while the highest expression of OCN and OP were 
observed after 28 days in scaffolds cultured in osteogenic medium.  The conclusions suggest that 
titanium/hASC construct could be used as an alternative in bone tissue engineering applications.   
In another in vitro study, Marino et al. evaluated the osteogenic potential of human adipose 
stem cells (fibroblast-like adipose tissue-derived stromal cells—ADSC-FL) isolated from 5 





 cells/disc) and cultured in control or osteogenic  media for 
several different time points
34
.  The findings indicated that β-TCP alone could trigger osteogenic 
differentiation of ADSC-FL.  Alkaline phosphatase, OCN, and OP expressions were observed in 
cells cultured in both control and osteogenic media with expression of OCN and OP being higher 
after 14 and 28 days in cells cultured in osteoinductive medium.   
Similarly, Frohlich et al. also observed that perfusion culture of hASC on bovine 
decellularized bone scaffolds in the presence of osteogenic supplements contributed to the 
uniform distribution of cells and bone matrix within the constructs
41
.  In this study, the authors 
used a perfusion bioreactor system to load hASC onto a bovine decellularized bone scaffold.  
Subcutaneous adipose tissue was obtained from four female donors undergoing elective 





cells/40μL onto 0.37–0.45 mg/mm
3
 scaffolds using a perfusion bioreactor connected to a 
peristaltic pump (Ismatec, flow rate - 1.8 mL/min).  Immediately after incubation (1 hour), some 
seeded scaffolds were collected to assess the loading efficiency while other scaffolds were 
transferred in parallel to both static or perfusion cultures to assess the osteogenic differentiation 
of seeded scaffolds after 5 weeks in both control and osteogenic medium.  Treatment groups 
included: static-control, static-osteogenic, perfused-control, and perfused-osteogenic.  
Biochemical analysis revealed that ALP expression was higher in scaffolds cultured in 
osteogenic than in control medium after 4 weeks.  Calcium deposition as a mean of alizarin red 
and von kossa staining also corroborate these findings.  Moreover, uneven distribution of 
collagen, OP (after 2 and 5 weeks) and BSP (after 5 weeks) were observed in the statically 
cultured constructs supplemented with osteogenic medium, while uniform spatial distribution of 
all three proteins were observed in constructs cultured in the perfusion bioreactor.  In summary, 
these in vitro studies demonstrated that the composition of the scaffolds can modulate the 
osteogenic differentiation of hASC.  Moreover, perfusion bioreactor culture system improved the 
homogenenity of osteogenesis and positively correlated with increased bone mineralization 
within scaffolds after 5 weeks.  
 The osteogenic effect of hASC loaded to different scaffold materials was also observed in 
2010 in three different in vivo studies.  In the first study, Muller et al. investigated the osteogenic 
and vasculogenic potentials of fibrin gels embedded with freshly isolated human SVF cells and 
seeded on commercially available ceramic scaffolds to assess the feasibility of an intraoperative 
approach to enhance bone healing in a setting compatible to clinical situations
40
.  Subcutaneous 
adipose tissue was obtained from 11 individuals undergoing (10 female, 1 male; mean age 32 
years) elective abdominal wall plasty (n=5), breast reduction (n=3), or liposuction of the thigh 
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(n=2) and the abdominal wall (n=1), respectively.  Freshly isolated SVF containing variable 
fractions of mesenchymal and endothelial progenitors were loaded in 4mmX8mm β-TCP 














) and a fibrin hydrogel was adhered to each construct to serve as a cell carrier before 
subcutaneously implantation in nude mice. Eight weeks after implantation, the authors concluded 
that no major qualitative differences in the formation of dense matrix or blood vessels were 
observed between the scaffold groups.  Even though dense collagen matrix was observed in 
samples stained with H&E and Masson’s trichrome, no effective de novo bone formation could 
be observed, suggesting that SVF alone without short term osteoinductive stimulation poorly 
modulated osteogenic differentiation on scaffolds.  In the second
 
study, Levi et al. loaded hASC 
to apatite-PLGA composites and surgically implanted them into calvarial defect in nude mice
51
.  
Human ASC were harvested from female lipoaspirate.  Critical-sized (4 mm) calvarial defects 
were created in the parietal bone of adult male nude mice.  Defects were either left empty, 
treated with an apatite coated PLGA scaffold alone, or a scaffold with hASC.  Cells were shown 
to persist within a defect site for two weeks (shown by sex chromosome analysis and quantified 
using Luciferase+ ASCs).  Finally, recombinant BMP-2 (rBMP-2) was observed to increase 
hASC osteogenesis in vitro and osseous healing in vivo.  The authors concluded that hASC 
ossified critical sized mouse calvarial defects without the need for pre-differentiation and that 
recombinant differentiation factors such as BMP-2 may be used to supplement hASC mediated 
repair.  These two studies, indicated that SVF processing and implantation can be performed 
within real clinical setting situations.  Moreover, repair of calvarial defect strongly suggested that 
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hASC-scaffolds can be used in the treatment of human skeletal defects as previously 
demonstrated
3
.   
 The last in vivo study performed in 2010 investigated if alendronate (Aln), a bisphosphonate 
commonly used to treat osteoporotic patients, could enhance the in vitro and in vivo human 
adipose-derived stem cells (hADSCs) osteogenesis
43
.  Wang et al. isolated hADSCs from the 
adipose tissue collected in 4 patients (age range, 20-36 years) admitted for elective hip 
replacement surgery.  For the in vitro study, untreated hADSCs (control) or cells treated with 
increasing doses of Aln were cultured for 5 days in osteogenic medium.  Immediately after, 
hADSCs (control and Aln-treated) were transferred into osteogenic medium and cultured for 14 
days.  For the in vivo study, porous PLGA discs (2mmX2mm) were pre-wetted, loaded with 
1X10
6
 cells (one donor only) and incubated overnight before discs were placed in surgically 
created 7-mm calvarial defects in male Spraguee Dawley rats for 12 weeks post-implantation.  
Animals were separated in four groups with local injections of PBS or Aln (5 µM) performed 4 
days post-implantation: PLGA alone + PBS; PLGA alone + Aln; hADSC/PLGA + PBS; and 
hADSC/PLGA + Aln.  The findings of the in vitro study indicated that BMP-2 expression, ALP 
activity and alizarin red staining were enhanced in hADSCs pre-cultured with 5 µM Aln.  Even 
though different degrees of bone in-growth were observed in all treatment groups, maximal new 
bone formation in critical-sized calvarial defects and BMP-2 expression were observed after 12 
weeks in rats treated with local injection of Aln after implantation of hASDC-PLGA scaffold 
discs. The authors conclude that a combination of local, short-term Aln treatment with hADSCs 
and biodegradable PLGA enhanced the bone repair of a calvarial defect.   
 Studies performed in 2010, indicated that hASC-scaffold osteogenesis may be influenced by 
the scaffold composition.  Moreover, complete cell processing to implantation can be performed 
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within real clinical setting situations.  Finally, in osteoporotic patients, fracture treatment could 
one day be enhanced by combining local, short-term Aln treatment with hASC-scaffolds.  
 In 2011, during the preparation of this publication, only two published studies have 
combined hASC with scaffolds
32,42
.  Weinand et al. compared the osteogenic potential of hASC 
to hBMSCs in third-generation gelatin/β-TCP scaffolds incorporated with controlled-release 
BMP-2
32
.  Four different group combinations were evaluated in vitro at several time points.  
Density compared to native bone was observed at 6 weeks in scaffolds incorporated with 
controlled-release BMP-2.  Gene expression of osteogenic markers as well as von kossa staining 
indicated similar bone formation in all group combinations (hBMSC, hASC, osteogenic or 
control media) in gelatin/beta-TCP scaffolds incorporating controlled-release BMP-2.  The 
authors concluded that hASC and hBMSC treated with osteogenic or control media have similar 
osteogenic potential.   
Lee et al. looked at the in vitro and in vivo osteogenesis of hASC transfected with osteogenic 
transcription factors to investigate if electroporation could be safely used as an alternative to 
viral transfection methods in bone tissue engineering applications
42
.  Passage 2 of hASC 
lipoaspirated from three patients (mean age, 41 years) were electroporated with Runx2, Osterix, 
or both genes.  The in vitro osteogenesis of transfected cells (passage 3) cultured in osteogenic 
medium was observed after 14 days in two groups: cells only or cells injected into 5mmX2mm 
PLGA scaffolds (1X10
6
 cells/scaffold).  Scaffolds were also subcutaneously implanted in nude 
mice to investigate if transfected cells promoted ectopic bone formation 6 weeks after 
implantation.  In this case, groups composed of PLGA scaffolds only, PLGA-untransfected 
ASCs and PLGA-transfected ASCs treated with EGFP-C1 were used. Compared to untransfected 
cells (control), Runx2, Osterix, or both as well as the osteogenic markers ALP, COL1, OCN and 
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BSP were overexpressed after 7 and 14 days in transfected cells.  Von Kossa staining of PLGA 
scaffolds loaded with hASC transfected with Runx2, Osterix, or both genes also showed greater 
mineralization than in scaffolds loaded with control cells after 14 days of culture in osteogenic 
medium.  Six weeks post-implantation, mineralization of scaffolds loaded with hASC transfected 
with Runx2, Osterix, or both genes was also observed in nude mice using μ-CT and Masson’s 
trichrome staining.  The findings indicated ectopic bone formation was greater in mice implanted 
with scaffolds loaded with electroporated hASC than in mice implanted with scaffolds with 
untreated control cells, while no mineralization was observed in mice implanted with scaffolds 
only.  The authors concluded that electroporation-mediated transfer of Runx2 or Osterix genes 
enhanced the in vitro and in vivo osteogenenic differentiation of hASC.  These studies together, 
have so far indicated that hASC osteogenesis can be modulated in a scaffold microenvironment.  
From all the studies performed in the decade following the first clinical evidence that hASC-
scaffolds can be used in humans
3
, two important points can be made.  The first and most obvious 
is that hASC osteogenesis in scaffolds has been demonstrated in both in vitro and in vitro studies 
using a variety of bioabsorbable materials.  Rats and nude mice models for non-weight bearing 
bone formation have led the way to assess hASC osteogenesis in vivo.  While 1
st
 generation 
scaffolds facilitate the attachment of hASC and subsequent cell proliferation, differentiation and 
in some cases neovascularization; their poor mechanical properties and brittle behavior are non-
ideal for future scaffold-assisted bone regeneration with hASC.  Composite scaffolds loaded with 
hASC have been shown to have better mechanical and biological properties and therefore may be 
preferred as scaffolding materials for hASC in future clinical trials.  The second point, and 
maybe the most important for the future of hASC-scaffold therapy, is also clear in the current 
reports.  Even though the field is still new, the lack of standardization in applied techniques (such 
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as scaffold fabrication, cell passages, loading techniques and medium preparations) makes the 
comparison between different studies difficult.  Perhaps, such agreements will be reached in the 
near future allowing for more facile comparisons between different studies.  With this important 
step, the use of hASC-scaffolds for bone regeneration would take a major step toward clinical 
trials and potential regulatory approval.  
1.4. Conclusions 
Since the first discovery of the hASC osteogenesis, research substantially progressed toward 
the use of hASC as stem cell source to regenerate bone.  Current strategies primarily
 
aim the in 
vitro characterization of the hASC osteogenic potential in novel or commercially available 
scaffolds combined or not with in vivo studies performed under non-weight bearing conditions in 
either rats or mice models for calvarial bone defects or subcutaneous ectopic bone formation.  
While 1
st
 generation scaffold materials have been demonstrated to facilitate the attachment and 
hASC differentiation, their major limitations today are their relatively poor mechanical 





 generation composites will be preferred as scaffolding materials for hASC in future tissue 
engineering applications. However, for scaffold-assisted bone tissue engineering combined with 
hASC become a reality, standardization of the current protocols is needed. 
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Chapter 2. Characterization of Novel Akermanite:Poly-E-Caprolactone Scaffolds for 
Human Adipose-Derived Stem Cells Bone Tissue Engineering 
 
2.1. Introduction 
Scaffold-assisted bone tissue engineering has been described as the alternative strategy to 
regenerate bone in the twenty-first century (Gaalen et al., 2008) because scaffolds can provide 
support for cell colonization, migration, growth, and differentiation in the fracture site (Lawrence 
and Madihally, 2010).  Of the adult pluripotent cells sources used in scaffold assisted-bone tissue 
engineering strategies, human adipose-derived stromal cells (hASC) are of particular interest 
because hASC can be obtained readily through minimally invasive procedures and scaffolds 
loaded with autologous hASC have been clinically demonstrated to be an effective treatment to 
promote bone growth and tissue repair in humans (Lendeckel et al., 2004).  To date, the scaffold-
hASC osteogenic potential has been investigated using a variety of tissue engineering 
techniques.  Recent studies have combined hASC with human autografts (Lendeckel et al., 2004; 
De Girolamo et al., 2008), acellular xenografts (De Girolamo et al., 2008; Muller and Mehrkens, 
2010; Frohlich et al., 2010), synthetic polymers (Hattori et al., 2004; Dégano et al., 2008; Wang 
et al., 2010; Lee and Lee, 2011), ceramics (Scherberich et al., 2007; Dégano et al., 2008; De 
Girolamo et al., 2008; Liu et al., 2008; De Girolamo et al., 2009; Haimi et al., 2009; Haimi and 
Suuriniemi, 2009; Haimi and Gorianc, 2009; Marino et al., 2010; Gastaldi et al., 2010; Muller 
and Mehrkens, 2010) and composite scaffolds (Leong et al., 2006; Jeon et al., 2008; Leong et al., 
2008; De Girolamo et al., 2009; Haimi and Suuriniemi, 2009; McCullen and Zhu, 2009; Zhang 
et al., 2009; Levi et al., 2010; Wang et al., 2010; Weinand et al., 2011).  While clinical trials to 
exploit the benefits of scaffold-hASC for orthopedic applications are not underway in humans 
(Gimble et al., 2010; Gimble et al., 2011), the search for improved osteogenic scaffold materials 
continues. 
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Ideal scaffold materials for future hASC bone tissue engineering strategies should be 
biocompatible, absorbable, easy to handle, capable of supporting hASC growth and 
osteoinductive with predictable mechanical and degradation properties during the healing 
process (Reichert and Hutmacher, 2011).  Autogenous bone grafts provide an osteoconductive 
matrix where self-osteoprogenitor cells can undergo osteogenesis through the synthesis and 
release of osteoinductive growth factors (Lendeckel et al., 2004; De Girolamo et al., 2008).  
However, the avaiability and the need for a secondary operative procedure are major limitations 
(Reichert and Hutmacher, 2011).  Allogeneic grafts are more easily obtained (De Girolamo et al., 
2008; Muller and Mehrkens, 2010; Frohlich et al., 2010), but cost, and concerns about disease 
transmission or implant rejection are remain concerns (Reichert and Hutmacher, 2011).  Several 
types of bone-substitute scaffolds used in combination with hASC have demonstrated 
osteoconductive and osteoinductive properties (Leong et al., 2006; Scherberich et al., 2007; De 
Girolamo et al., 2008; Jeon et al., 2008; Leong et al., 2008; Liu et al., 2008; De Girolamo et al., 
2009; Haimi et al., 2009; Haimi and Suuriniemi, 2009; Haimi and Gorianc, 2009; Marino et al., 
2010; McCullen and Zhu, 2009; Zhang et al., 2009; Gastaldi et al., 2010; Levi et al., 2010; 
Muller and Mehrkens, 2010; Wang et al., 2010; Weinand et al., 2011).   
Among the materials currently used in hASC bone tissue engineering strategies, β-tricalcium 
phosphate (β-TCP) is the most common (Leong et al., 2006; Leong et al., 2008; Liu et al., 2008; 
Marino et al., 2010; McCullen and Zhu, 2009; Zhang et al., 2009; Wang et al., 2010; Weinand et 
al., 2011).  β-TCP is a biocompatible synthetic apatite (Ca3P2O8) with osteoconductive and 
osteoinductive properties superior to natural bone hydroxyapatite (HA) (Gaalen et al., 2008; 
Wang et al., 2010). However, β-TCP has poor compressive strength (Miranda et al., 2008) and a 
high degradation rate (Bouler et al., 2000) making β-TCP a less than ideal choice for future 
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scaffold-hASC clinical trials.  Recently, Liu et al. (2008) compared the osteogenic potential of 
hASC loaded to β-TCP with another biocompatible synthetic apatite (akermanite).  The findings 
of this study indicated increased expression of osteogenic markers in hASC cultured on 
akermanite scaffolds.  Akermanite (Ca2MgSi2O7) is believed to have a stable degradation rate 
and result in superior bone deposition compared to β-TCP (Liu et al., 2008).  Moreover the Ca, 
Mg, and Si ion extracts of akermanite scaffolds have been linked to hASC osteogenesis via up-
regulation of extracellular signal-related kinase (ERK), a member of the mitogen-activated 
protein kinases (MAPKs) signaling pathway (Gu et al., 2011).  These findings together with the 
improved mechanical and degradation properties (Liu et al., 2008) make akermanite a potential 
candidate for future hASC-bone tissue engineering strategies.   
While current hASC osteogenesis strategies have been successfully demonstrated in either 
HA (Scherberich et al., 2007; Dégano et al., 2008; De Girolamo et al., 2009; Wang et al., 2010), 
β-TCP (Liu et al., 2008; Haimi and Suuriniemi, 2009; Zhang et al., 2009; Marino et al., 2010; 
Wang et al., 2010) and akermanite (Liu et al., 2008; Gu et al., 2011) ceramic scaffolds, the major 
limitations of 1
st
 generation bone-substitute scaffolds used today are their relatively poor 
mechanical properties and brittle behavior (Reichert and Hutmacher, 2011).  The latest 
innovation for bioactive and fiber-reinforced bioabsorbable composites is to use both bioactive 
and/or bioabsorbable ceramics and bioabsorbable polymeric fiber reinforcement in the same 
composite structure (Reichert and Hutmacher, 2011).  Current models for hASC bone tissue 
engineering have combined HA (Jeon et al., 2008; Levi et al., 2010) and β-TCP (Leong et al., 
2006; Leong et al., 2008; Haimi and Suuriniemi, 2009; McCullen and Zhu, 2009; Zhang et al., 
2009; Weinand et al., 2011) with poly(l-lactic acid-co-glycolic acid –PLGA) (Jeon et al., 2008; 
Levi et al., 2010), poly(lactic acid - PLA) (Haimi and Suuriniemi, 2009; McCullen and Zhu, 
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2009), gelatin (Weinand et al., 2011) and poly-e-caprolactone (PCL) (Leong et al., 2006; Leong 
et al., 2008; Zhang et al., 2009) but, to date, no attempts to develop an akermanite composite 
have been made.  
From a clinical stand point, moldable bone-substitute scaffolds are highly desirable (Kneser 
et al., 2006).  Among the synthetic polymers currently used as composite scaffolds in hASC 
applications, PCL is an attractive candidate for the development of moldable akermanite 
scaffolds because it is biocompatible, poorly water-soluble, has a slow degradation rate, low melt 
viscosity and a glass transition temperature well below physiologic temperature (Leong et al., 
2006; Gaalen et al., 2008; Leong et al., 2008; Zhang et al., 2009) allowing for facile molding.  
The objective of this study was to explore akermanite and PCL porous composite material as an 
alternative to pure ceramic or HA/β-TCP composites for support of hASC-combined bone tissue 
regeneration strategies.  The hypothesis of this study was that an akermanite:PCL composite 
would have greater compressive strength and comparable biocompatibility and osteoinductive 
potential to control ceramic scaffolds.  
2.2. Materials and Methods 
2.2.1. Synthesis of Akermanite 
Akermanite, Ca2MgSi2O7, was synthesized by ceramic methods with calcium carbonate 
(1.237 g, 12.4 mmol), magnesium carbonate (0.521 g, 6.2 mmol), and silicon dioxide (0.742 g, 
12.4 mmol) as the starting materials.  These materials were mixed and ground up thoroughly 
using an agate mortar and pestle.  The 2.5 g white powder mixture was then pressed into a pellet 
with hydraulic press (with approximately 1 metric ton of applied pressure) and then heated up 
multiple times in an open to air boat-shaped alumina crucible using a programmable box furnace 
to achieve the following net reaction: 
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2 CaCO3 + MgCO3 + 2 SiO2 → Ca2MgSi2O7 + 3 CO2 (g) 
The initial heat treatment was carried out at 950°C (after increasing the furnace chamber 
temperature from room temperature at rate of 100°C/h) for 48 hours.  This intermediate reaction, 
which involves the conversion of the carbonate starting materials to oxides, was then allowed to 
cool down back to room temperature by heat loss through the top exhaust port of the furnace.  
The pellet was then weighed to confirm the mass loss of approximately 0.8 g (or 18.5 mmol) of 
carbon dioxide.  Subsequent heat treatments involved additional grinding, pellet pressing, and 
heating the crude product at the dwell temperature of 1300°C (after ramping up the temperature 
from room temperature at rate of 100°C/h) for 48 hours.  Each 48 hour heat treatment was 
followed by cooling back to room temperature by furnace exhaust.  The number of heat 
treatments at 1300°C required was dictated by proof of desired product purity (as judged by 
powder X-ray diffraction) and typically varied with each batch from 2 to 3 times. 
2.2.2. Characterization of Akermanite by Powder X-Ray Diffraction 
Powder X-ray diffraction was performed for phase identification and sample purity 
confirmation on a Bruker D8 Advance powder diffractometer equipped with Cu Kα radiation 
source (λ = 1.54178 Å) and a germanium incident beam monochromator.  Intensities of 
diffracted X-rays were recorded at room temperature in 0.02° step size over a 2θ range of 15-60°.  
Experimental powder patterns of synthesized products were compared to single crystal data 
obtained from the Inorganic Crystal Structure Database (ICSD) in order to confirm sample purity 
and, if necessary, to identify possible impurities.  A list of crystallographic data used for 
comparison is the following:  CaO, ICSD 26959 (Gerlach, 1922); MgO, ICSD 29127 (Bragg, 
1920); Ca3MgSi2O8, merwinite, ICSD 26002 (Moore and Araki, 1972); and Ca2MgSi2O7, 
akermanite, ICSD 26683 (Warren, 1930). 
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2.2.3. Synthesis of Ceramic Scaffolds  
Akermanite and 60%β-tricalcium phosphate:40%hydroxyapatite (60:40 β-TCP:HA) powders 
(3 g) were suspended in polyvinyl alcohol aqueous solution (10 wt %) and stirred in a glass 
beaker to obtain a well-dispersed slurry (Liu et al., 2008).  Polyurethane foam templates were cut 
into the desired shapes (10mmX10mm and 10mmX4mm) to replicate a porous scaffold.  Then, 
the prepared foam templates were immersed in a glass beaker containing akermanite or 60:40 β-
TCP:HA slurry and compressed with glass stick to force the slurry to migrate into the pores of 
the foams which were then incubated at 60°C for 1 day.  After drying, the scaffolded materials 
(either akermanite or a 60:40 β-TCP:HA mixture) were placed in an open to air boat-shaped 
alumina crucible and heated in a programmable box furnace to 500°C (at rate of 50°C/h) and 
allowed to dwell at this temperature for 5 hours.  After allowing the furnace to cool to room 
temperature, the scaffolds were then heat treated at 1300°C (at rate of 60°C/h) for 3 hours and 
cooled to room temperature by furnace exhaust. 
2.2.4. Fabrication of PCL and Akermanite:PCL Scaffolds 
A 10% PCL solution in 8 ml of 1-4, dioxane was prepared and akermanite was added at 
weight (g) ratio of 0,0:0,8 (PCL); 0.2:0.6; 0.4: 0.4; 0,6:0.2 (25:75; 50:50; 75:25 akermanite:PCL 
wt.%) in a glass bottle.  The mixtures were molded into 10mmX4mm polydimethylsiloxane 
(PDMS) templates or in 17mmX10mm glass cylinder vials. Composites (akermanite:PCL) and 
pure PCL solutions were immediately frozen with liquid nitrogen with a drop ratio of 1 inch/hour  
using a unidirectionally thermally induced phase separation technique over 2 hours 
(10mmx10mm cylinders) or frozen at -20ᵒC overnight (10mmX4mm discs).  Post freezing the 
samples were immediately incubated in a freeze-drier for 48 hours. PCL or akermanite:PCL 
scaffolds were prepared for SEM, compression testing, degradation rate and cytotoxicity studies.  
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2.2.5. Scaffolds Ultrastructure Characteristics 
The morphology of the resulting specimens was observed by scanning electron microscopy 
(SEM; JSM-6610).  For SEM observations, the scaffolds were mounted on aluminum specimen 
stubs with gold-palladium using an SPI-module Sputter Coater at 7 mA for 2 min and 
immediately examined under SEM at 10 kV.  Scanning electron micrographs were evaluated 
with MetaMorph® Software package for Olympus.  The porosity of the scaffolds was 
determinate in triplicates by subtracting the total scanned electron micrograph area from the void 
space.  The pore size of the scaffolds was measured in triplicates (5 measurements/scanner 
electron micrograph) for each scaffold type.   
To analyze the cellular distribution in the scaffolds, hASC-scaffolds were fixed in 2% 
gluteraldehyde and 0.1M phosphate buffer (PB, pH 7.45) at 48ᵒC for 1 h.  The same buffer (PB, 
pH 7.45) was used twice to wash the samples, followed by dehydration series in ethanol (50%, 
70%, 90%, 95%, and 100%) before the samples were dried for mounting and coating as 
described above. 
2.2.6. Mechanical Test 
Three specimens per scaffold type with geometry of 10mmX10mm were compressed at room 
temperature using a hydraulic-mechanical testing machine (Instron-Model 5696) at testing rate 
of 5 mm/min and maximum compression strain of 90%.   
2.2.7. Degradation Rate in Stromal Medium
 
In vitro degradation of scaffolds cultured (1 scaffold/15 mL centrifuge tube) in 5 ml of stromal 
medium (Dulbecco’s modified Eagle’s medium (DMEM), 10% FBS, 1% triple antibiotic 
solution) was performed in triplicates after 7, 14 and 21 days.  Weight of dried scaffolds was 
collected from each scaffold at time point 0.  Briefly, weight loss was determined by incubation, 
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at 37°C in stromal medium, agitation on an orbital shaker incubator (Thermo Scientific) at each 
time point.  Before each measurement, scaffolds were trypsinized, rinsed in distilled water and 
freeze-dried for 48 hours.  The media extracts of the scaffolds were stored at 4°C for viability 
assays.  
2.2.8. Isolation of hASC and Culture 
Liposuction aspirates from subcutaneous adipose tissue were obtained from male (n = 1) and 
females (n = 2) subjects undergoing elective procedures.  All tissues were obtained with 
informed consent under a clinical protocol reviewed and approved by the Institutional Review 
Board at the Pennington Biomedical Research Center.  Isolation of hASC was performed as 
described elsewhere (Gimble et al., 2011). The initial passage of the primary cell culture was 
referred to as ‘‘Passage 0’’ (p0).  The cells were passaged after trypsinization and plated at a 
density of 5,000 cells/cm
2
 (‘‘Passage 1’’) for expansion on T125 flasks until 80% of confluence 
was reached.  Passage 2 of each individual was used for cell viability after acute exposure to the 
scaffold medium extracts and on scaffolds after loading using a spinner flask. 
2.2.9. MTT Assay and hASC-Cytotoxicity to Medium Extracts
 
The cellular viability of on scaffold cultures were determined using the cytotoxicity assay 
(MTT proliferation kit).  The media extracts from scaffolds after 7, 14 and 21 days of culture 
were filtered and then pipetted (100 μL/well) into a 96-well plate previously sub-cultured with 
hASC (3,000 cells/well) and incubated in a CO2 incubator at 37ᵒC containing 5% CO2 for 24 
hours.  After the 24-hours incubation period, 10 μL of the MTT reagent was added to the each 
well and re-incubated at 37ᵒC in 5% CO2 for 4 h.  Then, MTT detergent (100 μL) was added to 
each well and samples were incubated at 37ᵒC in 5% CO2 overnight.  Cell viability was measured 
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at wavelength of 590 nm using a plate reader.  Each experiment was performed in triplicates for 
hASC plated from each of the three donors (3 wells/donor).  
2.2.10. hASC Loading on Scaffolds and Culture 
Passage 2 of each donor (n = 3) was individually loaded to each scaffold type (10 
scaffolds/type/donor) using a custom-made spinner flask bioreactor at loading density of 1,300 
cells/mL for 2 hours.  Immediately after, scaffolds were transferred into 48-well plates and 
maintained in stromal medium for 21 days.  SEMs and live/dead staining (Cell viability®, 
Invitrogen – using a Leica DM RXA2 Deconvolution System) were performed at 7, 14 and 21 
days to assess hASC attachment and viability on scaffolds.  
2.2.11. Quantification of DNA on Scaffolds
 
Total DNA content was used to determine the number of cells on each scaffold as previously 
described (Liu et al., 2008).  Briefly, scaffolds were crushed and then incubated with 0.5 mL 
proteinase K (0.5 mg/mL) at 56ºC overnight.  The mixture was centrifuged at 108 g for 5 
minutes and then 50 µl aliquots were mixed with 50 µl Picogreen dye solution (0.1 g/mL, 
Invitrogen) in 96-well plates.  Samples were excited at 480 nm and total DNA concentration was 
compared to a standard curve generated from serial dilutions of hASC.  Scaffold without cells 
were used to subtract the background fluorescence emission from all readings. 
 
2.2.12. Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
 
Total RNA was extracted from cells and cell-scaffold using the Trizol reagent (Sigma).  RT-
PCR was performed using OneStep RT-PCR kit (Qiagen) and interleukin-6 (Il-6) forward (5’- 
CAGAAAACAACCTGAACCTTCCA -3’) and reverse (5’- 
GGCAAGTCTCCTCATTGAATCC -3’) to assess proinflammatory upregulation in hASC 
exposed to the medium extracts and on cells loaded to the scaffolds; and alkaline phosphatase 
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(ALP) forward (5’- AATATGCCCTGGAGCTTCAGAA -3’) and reverse (5’- 
CCATCCCATCTCCCAGGAA -3’) and osteocalcin (OCN) forward (5’- 
GCCCAGCGGTGCAGAGT -3’) and reverse (5’- TAGCGCCTGGGTCTCTTCAC -3’) to 
assess the osteogenic differentiation of hASC loaded to scaffolds at different time points.  
Reactions were performed with a MJ Mini Thermal Cycler (BioRad).  Water (negative), LPS-
treated cells (500 μg/mL) and hASC culture in osteogenic medium for 21 days were used as 
controls.  Samples were normalized (ΔCt) against the house keeping gene 18SrRNA.  Semi-
quantitative analysis of the gels was performed in duplicates by measuring the mean and 
intensity of each band with Photoshop.  The relative expression of the bands was calculated by 
dividing the absolute intensity of each target gene by the absolute intensity of the 18SrRNA 
bands.   
2.2.13. Statistical Analysis 
All results were expressed as mean±SEM.  Normality of the data was confirmed using the 
Shapiro-Wilk test (P < 0.001).  Data was analyzed with one or two-way analysis of variance 
(ANOVA), followed by Tukey’s minimum significant difference (MSD) post hoc test for 
pairwise comparisons of main effects.  For all comparisons, a P-value < 0.05 was considered 
significant. 
2.3. Results 
2.3.1. Synthetic Akermanite Purity Confirmation 
Representative powder x-ray diffraction patterns are provided in Figure 3 for akermanite 
ceramic.  The result after the initial heat treatment at 950°C (Figure 3a) shows diffraction peaks 
corresponding to the products of decarbonation, calcium oxide (2θ = 32.26°, 37.44°, and 53.96° 
which can be indexed as hkl = 1 1 1, 0 0 2, and 0 2 2, respectively) and magnesium oxide (2θ = 
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42.96° which can be indexed as hkl = 0 0 2).  Also the formation of the merwinite phase, 
Ca3MgSi2O8, can be observed by presence of major diffraction peaks (2θ = 33.42°, 33.56°, 
33.82°, and 47.60° which can be indexed as hkl = 0 1 3, 4 1 1, 0 2 0, and -4 2 2, respectively).  
Typically, the next heat treatment carried out at 1300°C results in the presence of two 
predominant mineralogical phases, akermanite and merwinite (Figure 3b).  After 2-3 successive 
heat treatments at 1300°C, the merwinite phase was eventually removed (or below the limits of 
detection) and a pure sample akermanite was prepared for scaffold formation (see Figure 3c for 
proof akermanite purity).   
2.3.2. Ultrastructure Characterization of the Scaffolds  
The scanning electron micrographs of the scaffolds revealed the formation of porous 
structures with varying porosity and pore size (Figures 4AB).  Scaffolds composed of PCL 
(Figure 4d) and different akermanite:PCL combinations (25:75, 50:50 and 75:25 - Figures 4e-f, 
respectively) had the highest porosities which averaged 89% (89.09±2.73) and were at least 1-
fold greater than the porosities reported for CellCeramic
TM
 (82.50±0.50 - Figure 4a), 60:40 β-
TCP:HA (58.00±3.00 - Figure 4b) and akermanite (55.00±4.00 - Figure 4c) (P < 0.05). 
CellCeramic
TM
 scaffolds had the greatest pore size  (280 μm ±37.44), followed by 75:25 (118.20 
μm ±8.82) and 25:75 (103.60 μm ±7.28) akermanite:PCL scaffolds as well as akermanite 
(98.57±18.92), all of which had pores significantly greater than those observed in PCL 
(73.2±2.417) and 60:40 β-TCP:HA (55.99±7.486 ) scaffolds.  
2.3.3. Compression Test 
At maximum strain, 25:75 akermanite:PCL scaffolds displayed the highest strength (9831 


















Figure 3.  Powder x-ray diffraction patterns for akermanite ceramic.  In (a) the formation 
of decarbonation, calcium oxide and magnesium oxide and merwinite are shown after the 
initial heat treatment at 950°C.  In (b), the predominant presence of akermanite and 
merwinite after heat treatment at 1300°C.  Finally in (c), the presence of pure akermanite is 


























Figure 4. Porosity (A) and pore size (B) of CellCeramic
TM
 (a), 60:40 β-TCP:HA (b), 
akermanite (c), PCL (d) and the akermanite:PCL combinations (75:25; 50:50; 25:75 – e-f, 






4320±1459) and PCL (4387±43.55) which had similar compression strength but were 
statistically stronger than akermanite (1598±415) scaffolds.  Among the scaffolds, 60:40 β-
TCP:HA (743.90±43.55) and CellCeramic
TM
 (607.70±7.65) had the lowest strengths (Figure 5).  
2.3.4. In vitro Scaffold Degradation 
Figure 6 shows the degradation of the scaffolds in stromal medium as a function of the dry 
mass lost (%) over a 21 days period.  In general, 60:40 β-TCP:HA (91.34±0.51), CellCeramic
TM 
(90.34±0.50) and akermanite (89.97±0.17) lost the most mass after 7 days, followed by PCL 
(93.28±0.40) and the three akermanite:PCL combinations (25:75 - 97.98±0.45; 50:50 - 
97.34±0.33; 75:25 - 96.14±0.12).  After 14 days, akermanite scaffolds dissolved the most in 
stromal medium (74.42±0.482), with comparable loses in CellCeramic
TM 
(81.33±0.11) and 60:40 
β-TCP:HA (83.24±0.12) which degraded more than PCL (89.34±0.367) and two 
akermanite:PCL scaffolds (50:50, 89.78±0.11; 75:25, 89.34±0.57).  Within this time point, 
scaffolds composed of 25:75 akermanite:PCL had the lowest mass loss.   
The percentage of dry weight lost after 21 days was the greatest in CellCeramic
TM 
(73.26±0.59), 60:40 β-TCP:HA (76.19±0.49) and akermanite (72.76±0.17) scaffolds, followed 
by comparable loses in the 75:25 (82.76±0.29) and 50:50 (83.40±0.33) akermanite:PCL 
scaffolds.  At the end of this experiment, PCL (87.01±0.17) and 25:75 (88.62±0.51) 
akermanite:PCL scaffolds had the lowest dry mass losses.  
The percentage of dry weight lost after 21days was the greatest in CellCeramic
TM 
(73.26±0.59), 60:40 β-TCP:HA (76.19±0.49) and akermanite (72.76±0.17) scaffolds, followed 
by comparable loses in the 75:25 (82.76±0.29) and 50:50 (83.40±0.33) akermanite:PCL 
scaffolds.  At the end of this experiment, PCL (87.01±0.17) and 25:75 (88.62±0.51) 

















Figure 5. Compression strength in cylindrical discs 
(10mmX10mm). The images are depicting the deformed 













Figure 6. Percentage of dry weight loss in scaffolds immersed in stromal media and incubated 
in a shaker at 37ᵒC over a 21 days period.  The asterisks indicate significant differences in the 










2.3.5. Viability of hASC After Acute Exposure to the Media Extracts of Different Scaffolds 
(The MTT Assay)  
 
The hASC 24 hours exposure to the media extracts collected from the tested scaffolds after 7, 
14 and 21 days revealed distinct metabolic activity patterns (Figure 7A) and cell behaviors 
(Figure 7a-u) as a function of scaffold composition.  For the media extracts collected after 7 
days, the hASC metabolic activity was the highest in cohorts subjected to akermanite (0.22±0.01 
- Figure 7m) and the akermanite:PCL combinations (75:25, 0.22±0.01 - Figure 7g; 50:50, 
0.21±0.01 - Figure 7d; 25:75, 0.19±0.01 - Figure 7a) which were significant greater than the 
metabolic activity observed in hASC exposed to PCL (0.11±0.01- Figure 7j), followed by 60:40 
β-TCP:HA (0.04±0.01- Figure 7p) and CellCeramic
TM
 (0.01±0.01- Figure 7s) (P < 0.05).  After 
14 days, the metabolic activity of the hASC as a function scaffold content revealed comparable 
metabolic patterns in hASC exposed to akermanite (0.18±0.01- Figure 7n) and 25:75 
akermanite:PLC (0.18±0.01- Figure 7b), however these values were significantly greater than the 
values observed in hASC exposed to 75:25 (0.12±0.02- Figure 7h) and 50:50 (0.11±0.02- Figure 
7e) akermanite:PCL media extracts, CellCeramic
TM
 (0.10±0.01- Figure 7t) and PCL (0.10±0.01 - 
Figure 7k).  After 14 days, the metabolic activity of hASC exposed to 60:40 β-TCP:HA 
(0.04±0.01 - Figure 7q) media extracts was the lowest among the tested scaffolds (P < 0.05).   
The metabolic activity of hASC exposed media extracts collected after 21 days was the 
highest in hASC exposed to akermanite (0.20±0.01 - Figure 7o) and 25:75 akermantie:PCL 
(0.20±0.01 - Figure 7c) which were significantly greater than PCL (0.16±0.01 - Figure 7l), 
CellCeramic
TM
 (0.11±0.01 - Figure 7u), 60:40 β-TCP:HA (0.08±0.01 - Figure 7r) and two of the 
akermanite:PCL combinations (75:25, 0.04±0.01 - Figure 7i; 50:50, 0.03±0.01 - Figure 7f).  
In general, hASC detachment during acute exposure to scaffolds media extracts at different 
time points was not observed in cohorts exposed to PCL (Figures 7j-l), akermanite (Figures 7m- 
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Figure 7. Viability of hASC (n = 3 donors) after acute exposure (24 hours) to the media 
extracts of different scaffolds. In A, the cell proliferation of hASC, determinate by the 
MTT assay, indicate the hASC metabolic activity after expose to different media extracts.  
In B, the gels and the semi-quantitative analysis of the Il-6 relative expression are 
depicted after hASC acute exposure to different media extracts at 7, 14 and 21 days. The 
asterisks indicate significant differences in the metabolic activity and the Il-6 relative 
expression within different time points for each one of the scaffold media extracts.  
Inserts indicate the hASC behavior after acute exposure to scaffold media extracts at 7, 
14 and 21 days.  Briefly, 25:75 akermanite:PCL (a-c), 50:50 akermanite:PCL (d-f), 75:25 
akermanite:PCL (g-i), PCL (j-l), akermanite (m-o), 60:40 β-TCP:HA (p-r) and 
CellCeramic
TM
 (s-u). Scale bars 1040 μm, 2X.  
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o), 60:40 β-TCP:HA (Figures 7p-r) and CellCeramic
TM
 (Figures 7s-u).  However, increased 
number of detached hASC were observed after acute exposure to the three akermanite:PCL 
combinations tested in this study (Figures 7a-i).  In the media extracts collected after 7 days, 
hASC detachment was not observed in hASC exposed to 25:75 akermanite:PCL media extracts 
(Figure 7a), however hASC detachment was observed in the cohorts exposed to 50:50 (Figure 
5d) and 75:25 (Figure 7g) akermanite:PCL media extracts, respectively.  In hASC exposed to the 
akermanite:PCL media extracts after 14 days of culture, increased numbers of detached hASC 
were observed in all three akermanite:PCL combinations (Figures 7b,e,h).  Likewise, hASC 
exposure to the media extracts of akermanite:PCL scaffolds cultured for 21 days yielded highest 
number of detached cells, especially in hASC exposed to 75:25 akermanite:PCL media extracts 
(Figure 7i). 
2.3.6. Semi-Quantitative RT-PCR Analysis After hASC Acute Exposure to Media Extracts  
The relative expression of Il-6 mRNA changed significantly over time in hASC exposed to 
all media extracts, with the exception cells exposed to the 25:75 akermanite:PCL media extracts 
(Figure 7B).  After 7 days, the relative expression of Il-6 was highest in hASC exposed to the 
media extracts collected from CellCeramic
TM 
(1.14±0.01) and 25:75 akermanite:PCL 
(1.18±0.01) with no significant differences observed between them, followed by significant 
differences between 50:50 akeramanite:PCL (0.77±0.02) and PCL (0.74±0.01) which were 
comparable between each other but significantly greater than 75:25 akermanite:PCL (0.65±0.01) 
and 60:40 β-TCP:HA (0.62±0.01) which were statistically greater than the Il-6 expression 
observed in hASC exposed to the akermanite (0.23±0.01) media extracts. 
In the hASC exposed to media extracts collected after 14 days of culture, the Il-6 expression 
was the highest in hASC exposed to the 25:75 akermanite:PCL media extracts (1.22±0.01), with 
60 
comparable Il-6 expression between 50:50 akermanite:PCL (1.01±0.02) and CellCeramic
TM
 
(0.97±0.01) media extracts which were both statistically greater than 75:25 akermanite:PCL 
(0.89±0.01), PCL (0.71±0.01) and 60:40 β-TCP:HA (0.50±0.01).  Within the same time point, 
the Il-6 expression was the lowest in hASC exposed to akermanite media extracts (0.22±0.01).   
For the media extracts of scaffolds collected after 21 days, the Il-6 expression was the highest 
in hASC exposed to CellCeramic
TM 
(1.59±0.01), followed by comparable Il-6 expression 
between hASC expose to PCL (1.23±0.01), 75:25 (1.20±0.02) and 25:75 (1.19±0.01) 
akermanite:PCL media extracts which were significantly greater than 50:50 akermanite:PCL 
(1.05±0.02) and 60:40 β-TCP:HA (0.72±0.01).  The lowest Il-6 expression in hASC exposed to 
scaffolds media extracts collected after 21 days of culture was observed in hASC exposed to 
akermanite media extracts (0.36±0.01). 
2.3.7. Viability of hASC on Scaffolds 
Spinner flask bioreactor yielded in average a loading efficiency of 67% (66.71±5.16) with no 
significant differences between scaffold types.  In the summary provided in Figure 8, the 
viability of hASC loaded to akermanite:PCL scaffolds 25:75 (Figure 8a), 50:50 (Figure 6d) and 
75:25 (Figure 8g) measured by the Live/Dead staining after 7 days was lowered than in the 
control ceramic scaffolds (akermanite - Figure 8m; 60:40 β-TCP:HA - Figure 8p; CellCeramic
TM
  
- Figure 8s) but greater than in PCL alone (Figure 8j), with increased number of viable hASC in 
75:25 akermanite:PCL scaffolds.  After 14 and 21 days of culture, increased number of viable 
hASC was observed in akermanite (Figure 8n-0), 60:40 β-TCP:HA (Figure 8q-r), CellCeramic
TM
 
(Figure 8t-u) and 75:25 akermanite:PCL (Figure 8h-i) compared to PCL (Figure 8k-l) and the 
other akermanite:PCL scaffolds (25:75 and 50:50, Figures 8b-c and e-f, respectively).   
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2.3.8. DNA Quantification on Scaffolds (The Picogreen Assay) 
Considering the hASC proliferation on different scaffolds (Figure 9A), after 7 days the 
highest DNA content was observed in 75:25 akermanite:PCL (70240±22501.80 - Figure 10g) 
and akermanite (59181.67±11948.23 - Figure 10m) which had DNA content significantly greater 
than CellCeramic
TM 
(41640±4484.65 - Figure 10s) and 60:40 β-TCP:HA (40665±7908.80 - 
Figure 10p) and the two akermanite:PCL (50:50, 28720±7229.06 - Figure 10d; 25:75, 
27578.33±4708.83 - Figure 10a) scaffolds.  After 7 days, the DNA content was the lowest in 
PCL scaffolds (7356.66±828.07 - Figure 10j).  After 14 days, the DNA content in 60:40 β-
TCP:HA (377700±5654.08 - Figure 10q) was the highest, followed by akermanite 
(293816.70±27296.70 - Figure 10n), CellCeramic
TM
 (215666.70±8920.15 - Figure 10t) and the 
akermanite:PCL scaffolds (25:75, 179123.30±51537.14 - Figure 10b; 50:50, 
162813.30±33623.31 - Figure 10e; 75:25, 207240±53526.80 - Figure 10h) which had 
comparable DNA content.  Within this time point, the lowest DNA content was observed in PCL 
scaffolds (87756.66±10172.56 - Figure 10k).   
After 21 days in culture, increased DNA content was observed in both akermanite 
(436716.70±31693.88 - Figure 10o) and CellCeramic
TM 
(511316.70±44057 - Figure 10u) 
scaffolds which were significantly greater than the DNA contents observed in 60:40 β-TCP:HA  
(319066.70±2419.32 - Figure 10r), the 50:50 (213580±62017.20 - Figure 10f) and 75:25 
(252968.30±73711.24 - Figure 10i) akermanite:PCL scaffolds and the 25:75 akermanite:PCL 
(120111.70±28936.16 - Figure 9c).  At the end of the experiment, the lowest DNA content was 
























Figure 8. Live (green) and Dead (read) stain of the scaffolds loaded with hASC (n = 3 
donors) after 7, 14 and 21 days of culture.  Briefly, 25:75 akermanite:PCL (a-c), 50:50 
akermanite:PCL (d-f), 75:25 akermanite:PCL (g-i), PCL (j-l), akermanite (m-o), 60:40 
β-TCP:HA (p-r) and CellCeramic
TM























Figure 9. hASC proliferation, cytotoxicity and osteogenic differentiation in different scaffolds after 7, 14 
and 21 days.  In A, DNA quantification of hASC on different scaffolds, determinate by the Picogreen 
assay. In B, the gels and the semi-quantitative analysis of OCN, Il-6 and ALP relative expression are 
depicted after different culture periods.  For A and B, significant differences over time in the DNA content 
and the relative expression of OCN, Il-6 and ALP within the same time scaffold type are represented by 
different lowcase letters.  
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2.3.9. Semi-Quantitative RT-PCR Analysis of hASC Loaded to Scaffolds Using a Spinner 
Flask 
 
The relative expression of Il-6 mRNA in hASC cultured on scaffolds was observed within 
each time point (Figure 9B).  After 7 days, the highest relative expression was observed in hASC 
loaded to 50:50 akermanite:PCL (4.56±0.01), followed by 25:75 akermanite:PCL (3.74±0.03) 
which was significantly greater than PCL (3.15±0.03), 60:40 b-TCP:HA (2.97±0.01) and 
akermanite (2.46±0.01).  The lowest Il-6 expression within the first week was observed in hASC 
loaded to 75:25 akermanite:PCL (0.45±0.02) and CellCeramic
TM 
(0.32±0.01) scaffolds.  After 14 
days, hASC loaded to 60:40 b-TCP:HA had the highest relative Il-6 expression (7.34±0.02), 
followed by two of the akermanite:PCL scaffolds (50:50, 4.83±0.01; 25:75, 4.49±0.01) which 
did not differ between each other but were statistically greater than PCL (3.96±0.01) and 
akermanite (2.37±0.01).  After 14 days the lowest Il-6 expression were observed in cells cultured 
on 75:25 akermanite:PCL (0.88±0.01) and CellCeramic
TM 
(1.14±0.01) scaffolds.  At day 21, the 
Il-6 relative expression was the highest in hASC loaded to 25:75 akermanite:PCL scaffolds 
(9.15±0.02), followed by 50:50 akermanite:PCL (6.04±0.02) and PCL (5.84±0.02) which were 
statistically greater than in hASC loaded to akermanite (4.85±0.02), 60:40 b-TCP:HA 
(4.56±0.01) and 75:25 akermanite:PCL (1.96±0.03).  After 21 days, hASC loaded to 
CellCeramic
TM
 (1.23±0.01) had the lowest Il-6 relative expression. 
In addition to Il-6, the relative expression of early (ALP) and middle (OCN) stage osteogenic 
markers were also investigated within the same time points (Figure 9B).  According to these 
results, after 7 days, the highest ALP relative expression was observed in hASC cultured on 
75:25 akermanite:PCL (1.51±0.01), followed by 50:50 akermanite:PCL (1.16±0.01) and 




 (0.24±0.01).  Cells cultured on PCL (0.07±0.01) and 60:40 b-
TCP:HA (0.02±0.01) had the lowest ALP relative expression after the first 7 days of culture.   
At day 14, hASC cultured on 25:75 akermanite:PCL (2.31±0.01) had the highest ALP relative 
expression, followed by 50:50 akermanite:PCL (1.86±0.015) which was significantly greater 
than 75:25 akermanite:PCL (1.62±0.01), akermanite (1.03±0.01) and CellCeramic
TM
 
(0.54±0.01).  Within this time point, the lowest ALP relative expression was again observed in 
hASC cultured on either PCL (0.07±0.01) and 60:40 b-TCP:HA (0.02±0.01) scaffolds.   
Cells loaded to 50:50 akermanite:PCL (2.64±0.05) and akermanite (2.35±0.01) had the 
highest ALP relative expression after 21 days of culture which was followed by 75:25 
akermanite:PCL (1.95±0.02), CellCeramic
TM
 (1.49±0.01), 25:75 akermanite:PCL (1.24±0.01) 
and PCL (0.18±0.01).  At day 21, the lowest ALP relative expression was again observed in 
hASC cultured on to 60:40 b-TCP:HA (0.02±0.01) scaffolds.   
Osteocalcin (OCN), a mid-stage marker of osteogenesis, after 7 days in culture, the OCN 
relative expression was constant among hASC cultured most of the scaffolds (Figure 9B) with 
the exception of hASC loaded to 75:25 akermanite:PCL (0.04±0.01) scaffolds which had a much 
lower expression.  A reversal was seen at 14 days, where the relative OCN expression in hASC 
cultured on 75:25 akermanite:PCL (0.41±0.01) was the highest, with similar expression in cells 
on CellCeramic
TM
 (0.13±0.01), 60:40 b-TCP:HA (0.14±0.03) and the other two akermanite:PCL 
scaffolds (25:75, 0.14±0.03; 50:50, 0.11±0.01) which were all significantly greater than PCL 
(0.09±0.01) and akermanite (0.05±0.03).  After 21 days, the OCN relative expression was the 
highest in hASC loaded to 75:25 akermanite:PCL (1.16±0.03), followed by comparable OCN 
expression in hASC loaded to CellCeramic
TM
 (0.27±0.01), 60:40 b-TCP:HA (0.18±0.01), 


























Figure 10. Scanning electron micrographs of hASC (n = 3 donors) loaded to different 
scaffolds at 7, 14 and 21 days of culture.  Briefly, 25:75 akermanite:PCL (a-c), 50:50 
akermanite:PCL (d-f), 75:25 akermanite:PCL (g-i), PCL (j-l), akermanite (m-o), 60:40 β-
TCP:HA (p-r) and CellCeramic
TM
 (s-u). Scale bars 200 μm. 
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50:50, 0.18±0.01) which were significantly greater than the OCN relative expression in hASC 
loaded to PCL (0.09±0.01) scaffolds.  
2.4. Discussion 
The aim of this study was to characterize a moldable akermanite:PCL composite scaffold for 
hASC bone tissue applications in terms of scaffold properties (porosity, pore size, compressive 
strength and degradation) and hASC viability, attachment, proliferation and osteogenic 
differentiation.  Three different akermanite:PCL blends were used to compare the referred 
parameters against PCL, akermanite, commercial CellCeramic
TM
 or custom-made 60:40 β-
TCP:HA scaffolds.  According to the results of this study, porous scaffolds composed of PCL 
and all three akermanite:PCL combinations had porosity greater than ceramic control scaffolds 
with the exception of CellCeramic
TM
 which had the greatest pore size.  When examining the 
compression strength of the same specimens, it can be seen that scaffolds composed of 25:75 
akermanite:PCL (% wt) were the strongest, followed by PCL while the other two 
akermanite:PCL composites (50:50 and 75:25) were statistically equal but significantly stronger 
than all ceramic scaffolds.  These results were predictable based on previous results of PCL-
based composites.  Incubation of scaffolds in stromal medium at 37ᵒC in an orbital shaker 
resulted in a significant mass loss from all ceramic scaffolds and two akermanite:PCL 
combinations (50:50; 75:25) in stromal medium which significantly influenced the metabolic 
activity and the expression of the proinflammatory cytokine Il-6 in hASC exposed to the 
scaffolds media extracts.  However, loading hASC onto the scaffolds using a spinner flask 
resulted in markedly different outcomes.  After 21 days in stromal medium, hASC loaded to 
composites made of 50:50 and 75:25 akermanite:PCL scaffolds had DNA content comparable to 
hASC loaded to custom-made 60:40 β-TCP:HA scaffolds.  Moreover, hASC cultured on 75:25 
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akermanite:PCL scaffolds had hASC similar viability after 21 days of culture, comparable to 
ceramic scaffolds.  The highest expression of mature osteoblast marker (OCN) was also found in 
cells cultured on the 75:25 akermanite:PCL scaffolds.  Together, the information provided in this 
study indicates that 75:25 akermanite:PCL composites are potential moldable scaffold candidates 
for future hASC bone tissue engineering applications.  
In this study, pure akermanite made by solid-state synthetic methods was used to create 
porous scaffolds, both pure ceramic and composite for mechanical, biocompatibility and 
osteogenic evaluation.  Custom synthesized 60:40 -TCP:HA scaffolds and commercially 
available (CellCeramic
TM
) were also prepared for comparisons.  Multi-phase ceramics containing 
a mixture of akermanite, merwinite, and dicalcium silicate have been recently studied (Chen et 
al., 2008) as potential osteogenic materials.  It should be noted that merwinite was demonstrated 
to promote osteogenesis and bone regeneration (Ou et al., 2008; Chen et al., 2010) and was 
carefully removed for the purpose of observing behavior of a pure akermanite phase.  Further 
investigations should be conducted to investigate if the merwinite phase plays a role in the 
akermanite biocompatibility and osteogenic differentiation. 
Porosity and pore size are critical for bone-substitute scaffolds because they facilitate cell 
migration and nutrient transport (Lawrence and Madihally, 2010).  In this study, the scaffolds 
fabricated by blending akermanite and PCL at different concentrations were highly porous and 
had pore diameter similar to the observed in native bone (Reichert and Hutmacher, 2011).  On 
the other hand, with the exception of CellCeramic
TM
, the low porosity and pore size observed in 
the other two control ceramic scaffolds is likely the result of the morphology of the polyurethane 
template used to fabricate the scaffolds.  The nature of this sacrificial template method results in 
pore-sizes dictated by the scale of the foam features. Nevertheless, scanning electron 
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micrographs taken at several time points revealed that hASC could adhere and proliferate in all 
scaffolds independent of the scaffold microarchitecture.  Migration into the scaffold was not 
assessed and it is likely that pore size will influence cell penetration depth by either size 
exclusion or reduced diffusion of nutrient and waste.     
Current scaffold-hASC bone engineering strategies assessed hASC osteogenesis under non-
weight bearing conditions (Hattori et al., 2004; Leong et al., 2006; Scherberich et al., 2007; 
Dégano et al., 2008; Jeon et al., 2008; Ahn et al., 2009; Zhang et al., 2009; Levi et al., 2010; 
Muller and Mehrkens, 2010; Wang et al., 2010; Lee and Lee, 2011).  However, future 
investigations assessing scaffold-hASC osteogenesis under compressive loads will rely, in part, 
on the mechanical properties of the scaffolds.  Ceramic scaffolds have poor mechanical 
properties and behavior in compressive load.  Issue which may in part be mitigated by the use of 
composite scaffolds due to their more robust and flexible mechanical properties (Reichert and 
Hutmacher, 2011).  Currently, only composites made of HA:PLGA (Jeon et al., 2008; Levi et al., 
2010) and β-TCP:gelatin (Weinand et al., 2011), β-TCP:PLA (Haimi and Suuriniemi, 2009; 
McCullen and Zhu, 2009) and β-TCP:PCL (Leong et al., 2006; Leong et al., 2008; , 2009; Zhang 
et al., 2009) have been proposed to support hASC osteogenesis.  In this study, at maximum 
compression strain of 90%, novel akermanite:PCL scaffolds (25:75 wt%) displayed the highest 
strength.  The presence of an inorganic phase significantly improved the PCL mechanical 
performance in the 25:75 akermanite:PCL scaffolds.  Similar result has been described for PCL 
scaffolds blended with HA (Fabbri et al., 2010).  However, at a higher akermanite wt% (50:50 
and 75:25 akermanite:PCL scaffolds) no significant differences between the two composites and 
pure PCL were observed.  The decreased PCL concentration in the blend might have influenced 
the stability of the composite scaffolds in a manner similar to that previously reported in 
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chitosan:PCL scaffolds by Sarasam et al. (2007).  Nevertheless, the fact that PCL has a gel 
transition phase close to the body’s temperature (Gaalen et al., 2008), makes a high akermanite 
weight content composite attractive for the development of moldable scaffolds.  Further 
investigations will be needed to assess the mechanical properties of akermanite:PCL composites 
under physiological load.  
Agitation significantly influenced the leaching of scaffold components into the media 
extracts.  In the literature, β-TCP has been shown to degrade at rates greater than akermanite 
(Bouler et al., 2000; Liu et al., 2008) in physiological solutions, but in this study under the 
continuous agitation, significant weight losses were observed in both ceramic scaffolds.  These 
results are similar to the increased weight loss associated with continuous agitation of akermanite 
scaffolds observed by Wu et al. (2006).  Among the akermanite:PCL scaffolds, leaching was 
shown to be ceramic phase concentration-dependent, with increased weight losses in high 
akermanite scaffolds (50:50 and 75:25).  It is well established that in aqueous environments, 
synthetic apatites degrade overtime through physiochemical dissolution and, possibly, phase 
transformation.  Depending on the concentration of the biomaterial this may result in decreased 
biocompatibility (Bouler et al., 2000; Chen et al., 2008; Chen et al., 2010).  The PCL phase of 
the composite is poorly water-soluble; has a melting temperature of 58 to 63ᵒC (Fabbri et al., 
2010); and degrades by surface hydrolysis of ester linkages with release of caproic acid which, 
has also been demonstrated to be cytotoxic at high concentrations (Sarasam et al., 2007).  For the 
hASC exposed to the media extracts of commercial and custom-made 60:40 β-TCP:HA scaffolds 
or PCL, the decreased metabolic activity and increased expression of proinflammatory cytokine 
observed in this study might had been the result of scaffolds phase transformation and 
cytotoxicity.  However, for the akermanite and akermanite:PCL scaffolds, recent information 
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indicated that the decreased hASC proliferation during the osteogenic differentiation of the cells 
after exposure to akermanite media extracts seems to be the result of DNA synthesis and cell 
division suppression rather than cell death (Gu et al., 2011).  This information might explain, in 
part, the decreased metabolic activity and the low expression of proinflammatory cytokine 
observed in hASC exposed to either scaffold type overtime, however, the fact that increased cell 
detachment was associated with high akermanite content in the akermantie:PCL scaffolds also 
indicated that the decreased hASC metabolic activity after exposure to the akermanite:PCL 
media extracts might had been the result of toxic changes in ion or caproic acid concentration in 
the media (Sarasam et al., 2007).  As a conclusion, the Il-6 profile presented in this study after 
exposure to the scaffolds media extracts is interesting and led to the assumption that high PCL, 
HA, β-TCP or combination of both (HA and β-TCP) triggered inflammation.  However, more 
studies are needed to address scaffold-hASC cytotoxicity in the molecular level.  Nevertheless, 
scaffold agitation might have played a critical role in the increased expression of this marker. 
Cell attachment to 3D scaffolds is crucial for clinical meaningful bone engineering.  
Therefore, a seeding technique resulting in a fast delivery is attractive to minimize the culture 
time in suspension for anchorage-dependent and shear-sensitive cells (Lawrence and Madihally, 
2010).  In this study, a custom-made spinner flask was used to load hASC to different scaffold 
types.  In principal, the technique relies on fluid convection and collision with the immobilized 
scaffolds to improve cell attachment and distribution throughout the scaffolds (Griffon et al., 
2010).  Even though, the spinner flask used in this study yielded high cell adherence immediately 
after loading, the number of hASC loaded on PCL and akermanite:PCL composites was overtime 
lower than the observed in the control ceramic scaffolds as determined by live/dead staining and 
DNA content.  Surface roughness is believed to influence cell adhesion and behavior (Yeo et al., 
72 
2010ab; Lawrence and Madihally, 2010).  Yeo et al. (2010ab) reported that β-TCP:PCL scaffolds 
with increased surface roughness displayed the highest cell growth and bone formation both in 
vitro and in vivo.  While this remains to be tested in the PCL and akermanite:PCL scaffolds used 
in this study, the increased live cell staining and DNA content observed overtime in the ceramic 
scaffolds could be the result of the increased surface roughness of the scaffolds.  For the 
akermanite:PCL scaffolds,  viability seemed to be akermanite dose-dependent as was observed 
after 14 and 21 days in hASC cultured on 75:25 akermanite:PCL scaffolds.  Recently, an 
increased number of studies had also indicated the increased viability of cells cultured on 
akermanite (Wu et al., 2006; Liu et al., 2008; Gu et al., 2011).   
In addition to Live/Dead staining and DNA content, this study also assessed scaffold 
biocompatibility to hASC in terms of Il-6 gene expression using semi-quantitative analysis.  
According to the results, hASC loaded to CellCeramic
TM
 and 75:25 akermanite:PCL scaffolds 
displayed the lowest expression of pro-inflammatory cytokine during the course of this study.  
However, the degree to which the expression of this marker is critical for scaffold 
biocompatibility still remains to be investigated in vivo.   
The ability to drive hASC osteogenesis is another key component of successful bone tissue 
engineering (Reichert and Hutmacher, 2011).  In this study, ALP was used as early osteogenic 
differentiation marker.  The highest ALP expression was observed after 7 days of culture on 
75:25 akermanite:PCL scaffolds, followed by pure porous akermanite and the other two 
akermanite:PCL combinations.  Compared to β-TCP, hASC cultured on akermanite also had a 
higher level of ALP activity after 10 days of culture (Liu et al., 2008).  For this study, OCN was 
also used as a marker for differentiation of mature osteoblasts.  The 75:25 akermanite:PCL 
scaffolds demonstrated the highest OCN expression after 14 and 21 days, indicating that the 
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75:25 akermanite:PCL composites may promote osteogenic differentiation of hASCs more 
effectively than the other tested scaffolds.  
In summary, the combined mechanical, biological and osteogenic properties of 75:25 
akermanite:PCL scaffolds are promising for bone repair applications when combined with 
hASC.  Further studies are needed to investigate the hASC osteogenic potential and 
biocompatibility of akermanite:PCL scaffolds in vivo. 
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Chapter 3. In Vitro Human Adipose-Derived Stem Cells Osteogenesis in Akermanite:Poly-
E-Caprolactone Bone Scaffolds 
3.1. Introduction 
Bone tissue engineering presents an alternative approach to the repair and regeneration of 
damaged bone tissue (Gaalen et al., 2008; Reichert & Hutmacher, 2011).  Bioceramics, 
especially calcium phosphate materials have been widely used for bone tissue repair due to their 
superior bioactivity (defined as biocompatibility, osteoconduction and osteoinduction) 
(Scherberich et al., 2007; Dégano et al., 2008; De Girolamo et al., 2008; Gaalen et al., 2008; Liu 
et al., 2008; De Girolamo et al., 2009; Haimi et al., 2009; Haimi & Suuriniemi, 2009; Haimi & 
Gorianc, 2009; Marino et al., 2010; Gastaldi et al., 2010; Muller & Mehrkens, 2010).  Among 
the different types of bioactive ceramics, the utilization of silica-based glasses in bone tissue 
engineering strategies have recently received considerable attention; particularly, because of 
their mechanical properties and enhanced bioactivity (Agathopoulos et al., 2005; Wu et al., 
2006a; Chen at al., 2010).  Moreover, due to the ability to form apatite-like layers at a 
physiological fluid interface, porous bioactive glasses have been shown to enhance cell adhesion, 
proliferation osteogenic differentiation, and extracellular matrix mineralization (Sun et al., 2006; 
Liu et al., 2008; Gu et al., 2011).  
As one kind of silica-based bioactive glass, akermanite (Ca2MgSi2O7) has shown to to 
enhance cell adhesion, proliferation and osteogenesis with a controllable degradation rate and 
desirable mechanical properties (Sun et al., 2006; Wu et al., 2006ab; Wu et al., 2007; Huang et 
al., 2009; Gu et al., 2011).  Akermanite is an end member of the melilite (sorosilicates); it has a 
high melting point (around 1450ᵒC); and exhibits increased stability, hardness, density and 
refractory properties (Zhuang et al., 1990; Yang et al., 1997; Wu et al.,2007).  Moreover, the Ca, 
Mg and Si content of akermanite have been shown to increase the calcium deposition and 
78 
 
osteogenic differentiation of human adult stem cells and mature osteoblast (Sun et al., 2006; Wu 
et al., 2006ab; Liu et al., 2008).  In human adipose-derived stem cells (hASC) the Ca, Mg, and Si 
ion extracts of akermanite scaffolds have been linked to hASC osteogenesis via up-regulation of 
extracellular signal-related kinase (ERK), a member of the mitogen-activated protein kinases 
(MAPKs) signaling pathway (Gu et al., 2011).  Human adipose-derived stem cells represent a 
readily available, autogenous cell source with well-documented in vivo osteogenic potential 
(Gaalen et al., 2008; Gimble et al., 2011).  Therefore, akermanite-based bone tissue engineering 
strategies resulting in enhanced hASC osteogenesis are appealing.  
The brittleness of pure bioactive glass ceramics is the major factor limiting their use in bone 
repair and making the translation to clinical settings difficult (Kneser et al., 2006; Gaalen et al., 
2008; Reichert & Hutmacher, 2011).  Recent innovations address this limitation by combining 
bioactive ceramics with bioabsorbable polymeric fiber reinforcement in the same composite 
structure (De Girolamo et al., 2009; Haimi & Suuriniemi, 2009; Zhang et al., 2009; Reichert & 
Hutmacher, 2011).  Of the many polymers compositions used in hASC bone tissue engineering 
applications, poly-e-caprolactone (PCL) is widely used as a resin for composite scaffolds (Leong 
et al., 2006; Gaalen et al., 2008; Reichert & Hutmacher, 2011).  PCL is a poorly water-soluble 
aliphatic polyester that has a slow in vivo degradation rate(Fabbri et al., 2010).  With a melting 
point close to the body temperature, current bone tissue engineering paradigms seek to utilize 
PCL as a moldable scaffolding material (Leong et al., 2006; Gaalen et al., 2008; Zhang et al., 
2009; Fabbri et al., 2010).  As both akermanite and PCL appear to have unique qualities suitable 
for bone tissue repair, we recently developed a novel composite scaffold (akermanite:PCL) to 
combine the desirable properties of both biomaterials.  In our previous study, we demonstrated 
that novel 75:25 (wt. %) akermanite:PCL composite scaffolds had compressive strength greater 
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than and bioactivity comparable to control ceramic scaffolds.  However, as part of the 
characterization of this new composite for bone tissue engineering applications, studies 
comparing the in vitro osteogenic potential of hASC loaded to akermanite:PCL in growth 
(control) and osteogenic media still remain to be conducted. 
Therefore in this study we compared the metabolic activity, calcium deposition and 
morphogical changes as well as the expression of markers associated with early and later 
osteogenic differentiation in hASC loaded to akermanite:PCL and cultured in growth or 
osteogenic media for up to 21 days.  The hypothesis of this study was that, compared to scaffolds 
cultured in control medium, osteogenesis, measured by decreased metabolic activity and 
increased calcium deposition and expression of osteogenic markers, would be greater in 
scaffolds cultured in osteogenic medium. 
3.2. Materials and Methods 
3.2.1. Synthesis of Akermanite 
Akermanite, Ca2MgSi2O7, was synthesized by ceramic methods with calcium carbonate 
(1.237 g, 12.4 mmol), magnesium carbonate (0.521 g, 6.2 mmol), and silicon dioxide (0.742 g, 
12.4 mmol) as the starting materials.  These materials were mixed and ground thoroughly using 
an agate mortar and pestle.  The 2.5 g white powder mixture was then pressed into a pellet with 
hydraulic press (approximately 1 metric ton of applied pressure) and then heated multiple times 
in an open to air boat-shaped alumina crucible using a programmable box furnace to achieve the 
following net reaction: 
2 CaCO3 + MgCO3 + 2 SiO2 → Ca2MgSi2O7 + 3 CO2 (g) 
The initial heat treatment was carried out at 950°C (after increasing the furnace chamber 
temperature from room temperature at rate of 100°C/h) for 48 hours.  This intermediate reaction, 
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which involves the conversion of the carbonate starting materials to oxides, was then allowed to 
cool to room temperature by heat loss through the top exhaust port of the furnace.  The pellet 
was then weighed to confirm the mass loss of approximately 0.8 g (or 18.5 mmol) of carbon 
dioxide.  Subsequent heat treatments involved additional grinding, pellet pressing, and heating 
the crude product at the dwell temperature of 1300°C (after ramping up the temperature from 
room temperature at rate of 100°C/h) for 48 hours.  Each 48 hour heat treatment was followed by 
cooling back to room temperature by furnace exhaust.  The number of heat treatments at 1300°C 
required was dictated by proof of desired product purity (as judged by powder X-ray diffraction) 
and typically varied with each batch from 2 to 3 times. 
3.2.2. Synthesis of Ceramic Scaffolds  
Akermanite and β-tricalcium phosphate (β-TCP) powders (3 g) were suspended in polyvinyl 
alcohol aqueous solution (10 wt %) and stirred in a glass beaker to obtain a well-dispersed slurry 
(Liu et al., 2008).  Polyurethane foam templates were cut into the desired shape and sizes 
(5mmX4mm) to replicate a porous scaffold.  Then, the prepared templates were immersed in a 
glass beaker containing akermanite or β-TCP slurry and compressed with glass stick to force the 
slurry to migrate into the pores of the foams which were then incubated at 60°C for 1 day.  After 
drying, the scaffolded materials (either akermanite or β-TCP) were placed in an open to air boat-
shaped alumina crucible and heated up in a programmable box furnace from room temperature 
(at rate of 50°C/h) to 500°C and allowed to dwell this temperature for 5 hours in order to burn 
off the polyurethane foam.  After allowing the furnace to cool down to room temperature by 
furnace exhaust, the scaffolds were then heat treated at 1300°C (increasing the furnace chamber 




3.2.3. Fabrication of PCL and Akermanite:PCL Scaffolds 
Composites (akermanite:PCL) and pure PCL solutions were frozen overnight at -80ᵒC  
(5mmX4mm discs).  A 10% PCL solution in 8 ml of 1-4, dioxane was prepared and akermanite 
was added at weight (g) ratio of 0,0:0,8 (PCL) and 0.6:0.2 (75:25 akermanite:PCL wt.%) in a 
glass bottle.  The mixtures were molded into 5mmX4mm polydimethylsiloxane (PDMS) 
templates and immediately incubated in a freeze-drier for 48 hours.   
3.2.4. Adult Stem Cells Isolation and Culture 
Liposuction aspirates from subcutaneous adipose tissue were obtained from male (n = 1) and 
females (n = 2) subjects undergoing elective procedures.  All tissues were obtained with 
informed consent under a clinical protocol reviewed and approved by the Institutional Review 
Board at the Pennington Biomedical Research Center.  Isolation of hASC was performed as 
described elsewhere (Gimble et al., 2011).  Briefly, tissues was washed 3–4 times with phosphate 
buffered saline and suspended in an equal volume of PBS supplemented with 1% bovine serum 
and 0.1% collagenase type I.  The tissues were placed in a shaking water bath at 37ᵒC with 
continuous agitation for 60 min and centrifuged for 5 min at 300–500 g at room temperature.  
The supernatant, containing mature adipocytes was then aspirated.  The cell pellet, referred to as 
the stromal vascular fraction (SVF), was suspended and plated immediately in T125 flasks in 
stromal medium at density of 0.156 ml of tissue digest/cm
2
 of surface area for expansion and 
culture.  The initial passage was referred to as ‘‘Passage 0’’ (p0).  The cells were passaged after 
trypsinization and plated at a density of 5,000 cells/cm
2
 (‘‘Passage 1’’) for expansion on T125 
flasks until 80% of confluence was reached.  Passage 2 of each individual was used for in vitro 
hASC osteogenesis alone or in different scaffold types.  In both cases, hASC were cultured in 
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either growth (control) or osteogenic media for up to 21 days with media maintenance performed 
three times a week.  
3.2.5. hASC Loading on Scaffolds and Culture  
Passage 2 of each donor (n = 3) were pooled and directly loaded on the top of each scaffold 
type at loading density of 5.0X10
4
 cells/5μL.  After 30 min of incubation at 37ᵒC and 5% CO2 an 
additional 5.0X10
4
 cells/5μL was directly loaded on the opposite side of each scaffold.  
Experimental groups included: 75:25 (% wt/v) akermanite:PCL, akermanite, PCL and β-TCP.  
Immediatelly after, scaffolds loaded with hASC were transferred to 48-well plates and cultured 
in control or osteogenic media (DMEM, 10% FBS, 0.1 μM dexamethasone, 50 μM ascorbate-2-
phosphate, 10 mM β-glycerophosphate, and 1% triple antibiotic solution) for 21 days with 
weekly sample collection to assess cell viability with Alamar blue stain; and osteogenic 
differentiation with alizarin red stain as well as mRNA expression of ALP and OCN.   
3.2.6. In vitro hASC Viability on Scaffolds with Alamar Blue Stain  
The viability of cells within the scaffolds at 7, 14 and 21 days in control and osteogenic 
media was determined using an Alamar Blue™ metabolic activity assay.  The scaffolds were 
removed from culture, washed three times in PBS, and incubated with 10% Alamar Blue™ in 
Hank’s balanced salt solution (HBSS) without phenol red (pH 7) for 90 min.  Aliquots (100 μL) 
of Alamar Blue™/HBSS were placed in a 96-well plate in triplicate, and the fluorescence was 
measured at an excitation wavelength of 530 nm and an emission wavelength of 595 nm using a 
fluorescence plate reader.   
3.2.7. In Vitro Calcium Deposition  
hASC osteogenesis (cells alone and cells-scaffolds) was assessed after 7, 14 and 21 days of 
culture in control and osteogenic medium using alizarin red stain.  Briefly, cells and scaffolds 
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were washed with 0.9% NaCl a total of four times (1 ml/well) and fixed with 70% ethanol (1 
ml/well).  Subsequently, the fixative was removed by aspiration and plates were stained with 2% 
alizarin red for 10 min and washed with H2O six times.  The samples were destained by the 
addition of 400 ml of 10% cetylpyridinium chloride monohydrate to each well followed by 
shaking for 10 min at room temperature.  The calcium deposition expressed by the optical 
density of the aliquots was then measured at 540 nm with a plate reader.  
3.2.8. Quantification of DNA on Scaffolds In Vitro
 
Total DNA content was used to determine the number of cells on each scaffold as previously 
described (Liu et al., 2008).  Briefly, scaffolds were crushed and then incubated with 0.5 mL 
proteinase K (0.5 mg/mL) at 56ºC overnight.  The mixture was centrifuged at 108 g for 5 
minutes and then 50 µl aliquots was mixed with 50 µl Picogreen dye solution (0.1 g/mL, 
Invitrogen) in 96-well plates.  Samples were excited at 480 nm and total DNA concentration was 
compared to a standard curve generated from serial dilutions of hASC.  Scaffold without cells 
were used to subtract the background fluorescence emission from all readings. 
 
3.2.9. Quantitative Real Time Polymerase Chain Reaction (QPCR)
 
Total RNA was extracted from cell-scaffolds using the Trizol reagent (Sigma).  QPCR was 
performed using 2X iTaq SYBR green with ROX (Biored) and alkaline phosphatase (ALP) 
forward (5’- AATATGCCCTGGAGCTTCAGAA -3’) and reverse (5’- 
CCATCCCATCTCCCAGGAA -3’) and osteocalcin (OCN) forward (5’- 
GCCCAGCGGTGCAGAGT -3’) and reverse (5’- TAGCGCCTGGGTCTCTTCAC -3’) to 
assess the osteogenic differentiation of hASC loaded to scaffolds at 7, 14 and 21 days in 
scaffolds culture in either growth and osteogenic media.  Reactions were performed with a MJ 
Mini Thermal Cycler (BioRad).  Water (negative) and hASC culture in osteogenic medium for 
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14 days were used as controls.  Samples were normalized (ΔCt) against the house keeping gene 
18SrRNA and the fold change expression of ALP and OCN in scaffolds cultured in osteogenic 
and control media was calculated using the ΔΔCt method (Liu et al., 2008).  
3.2.10. Statistical Analysis 
All results were expressed as mean ± SEM.  Normality of the data was confirmed using the 
Shapiro-Wilk test (P < 0.001).  Data was analyzed with one-way analysis of variance (ANOVA), 
followed by Tukey’s minimum significant difference (MSD) post hoc test for pairwise 
comparisons of main effects.  For all comparisons, a P-value of 0.05 was considered significant. 
3.3. Results 
3.3.1. Calcium Deposition in hASC Cultured in Control and Osteogenic Media 
Confirmation of the osteogenic potential of hASC isolated from three donors was assessed by 
staining hASC cultured in growth (control) and osteogenic media with alizarin red stain (Figure 
11).  In general, hASC cultured in osteogenic medium had calcium deposition significantly 
greater than control samples (P < 0.05).  Moreover, significant increase in the calcium deposition 
between different time points was also observed in hASC cultured in osteogenic medium.  
3.3.2. hASC Viability on Scaffolds Cultured in Control and Osteogenic Media 
hASC loaded on different scaffold types and cultured in both control and osteogenic media 
displayed significant changes in the metabolic activity during the course of this study.  The 
changes in the color of the scaffolds after alamar blue staining are represented in Figure 12A.   
After 7 days significant differences in the metabolic activity were observed for hASC 
cultured in control and osteogenic media in all scaffold types with the exception of hASC loaded 
to akermanite scaffolds,  (Figure 12B).  In general, the metabolic activity of hASC loaded to 
scaffolds cultured in control medium were significantly greater than scaffolds cultured in  
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Figure 11.  Alizarin red stain of hASC (Passage 2) cultured in growth (control) and osteogenic 
media for a 21 days period.  *Represent significant differences between the calcium deposition 





osteogenic medium.  Within the different scaffold types, after 7 days of culture in control 
medium, increased metabolic activity was observed in hASC loaded to akermanite:PCL scaffolds 
(232161.50±70531.34), with comparable levels in hASC loaded to PCL and β-TCP 
(176503.80±42308.36; 158579.70±15143.07, respectively, P > 0.05) and akermanite 
(74974.16±8632.26).    
After 14 days of culture, significant differences in the metabolic activity of hASC cultured in 
control and osteogenic media were observed only in hASC loaded to akermanite and PCL 
scaffolds (Figure 12B).  Compared to scaffolds cultured in osteogenic medium 
(174529.70±23776.19), the hASC metabolic activity in PCL scaffolds cultured in control 
medium was significantly higher after 14 days (359494.30±22494.01).  However, hASC loaded 
to akermanite scaffolds cultured in osteogenic medium (143524.20±2841.45) had metabolic 
acitivity significantly higher than the observed in control scaffolds (92600.16±1089.52).  After 
14 days of culture in control medium, comparable metabolic activity was observed in hASC 
loaded to akermanite:PCL (551391.80±199465.40) and PCL (359494.30±22494.01) scaffolds, 
which were significantly higher than comparable levels in β-TCP (105708.7±7404.53) and 
akermanite (92600.16±1089.52) scaffolds. 
Finally, after 21 days of culture, scaffolds cultured in both media conditions displayed 
comparable hASC metabolic activity with significant differences observed only between scaffold 
types (Figure 12B).  In general, after 21 days, hASC loaded to β-TCP scaffolds cultured in either 
control (320338.00±49213.05) or osteogenic (489036.00±51962.24) media had metabolic 
activity significantly higher than akermanite (control – 101356±1170.472; osteogenic – 
104408.00±1445.43) or akermanite:PCL (control – 98067.16±6166.95; osteogenic – 


































































































































































































































































































































































3.3.3. In Vitro hASC Calcium Deposition on Scaffolds 
Calcium deposition, as measured by alizarin red, on scaffolds loaded with hASC and cultured 
in both growth (control) and osteogenic media for 21 days is depicted in Figure 13.  In general, 
scaffolds had different accumulation of calcium after 21 days of culture in both media conditions 
(Figure 13A).  During the first 7 days of this study, significant changes in the calcium deposition 
on scaffolds cultured in growth (control) and osteogenic media were observed only in hASC 
loaded to β-TCP scaffolds (control – 0.211±0.067; osteogenic – 0.710±0.133, P < 0.05) (Figure 
13B).  However, between scaffold types, calcium accumulation in akermanite scaffolds cultured 
in either media conditions (control – 3.61±0.50; osteogenic – 3.58±0.05, P > 0.05) was, 
significantly higher than in akermanite:PCL scaffolds (control – 1.72±0.22; osteogenic – 
2.52±0.71, P > 0.05), β-TCP and PCL (control – 0.028±0.01; osteogenic – 0.12±0.03, P < 0.05) 
scaffolds.   
After 14 days of culture, significant differences in the calcium deposition were observed 
between growth (control) and osteogenic media only on akermanite scaffolds (control – 
2.47±0.13; osteogenic – 3.55±0.12, P < 0.05) (Figure 13B).  However, when analyzed for 
differences between scaffold types, akermanite scaffolds cultured in osteogenic medium had the 
highest calcium deposition, followed by comparable levels in akermanite scaffolds cultured in 
control medium and akermanite:PCL scaffolds cultured in either media conditions (control – 
1.92±0.39; osteogenic – 1.90±0.48, P > 0.05).  Both akermanite containing scaffolds had 
significantly higher values for calcium deposition than β-TCP (control – 0.37±0.10; osteogenic – 
0.62±0.16, P > 0.05) and PCL (control – 0.17±0.06; osteogenic – 0.11±0.03, P > 0.05) scaffolds.   








































































































































































































































































































































cultured in growth (control) and osteogenic media only akermanite (control – 3.31±0.04; 
osteogenic – 4.28±0.04, P < 0.05) and akermanite:PCL (control – 2.21±0.11; osteogenic – 
3.02±0.37, P < 0.05) scaffolds (Figure 13B).  When interscaffold differences are compared, 
akermanite scaffolds cultured in osteogenic medium had the highest calcium deposition, 
followed closely by comparable levels in akermanite scaffolds cultured in control medium and 
akermanite:PCL scaffolds cultured in osteogenic medium. These values were significantly higher 
than akermanite:PCL scaffolds cutured in control medium, β-TCP (control – 0.49±0.05; 
osteogenic – 0.89±0.72, P > 0.05) and PCL (control – 0.16±0.01; osteogenic – 0.21±0.05, P > 
0.05) scaffolds.  
3.3.4. In Vitro hASC Proliferation on Scaffolds Cultured in Control and Osteogenic Media 
Figure 14 depicts the total DNA content (cell proliferation) in scaffolds loaded with hASC 
and cultured under different media conditions for 21 days.  Significant differences in the cell  
proliferation was observed in scaffolds cultured in growth (control) and osteogenic media at 7 
days only in hASC loaded to β-TCP (control – 148152.00±44331.24; osteogenic – 
64021.33±1471.26, P < 0.05) and PCL (control – 188922.76±10699.14; osteogenic – 
46380.67±9538.36, P < 0.05) scaffolds.  When compared between scaffold types, cell 
proliferation was the highest in akermanite:PCL scaffolds cultured in both media conditions 
(control – 442218.70±169825.50; osteogenic –334082.00±95255.57, P > 0.05), followed by PCL 
and β-TCP scaffolds (both cultured in control medium), which were significantly higher than 
either akermanite (control – 38913.33±9004.578; osteogenic – 47062.33±8730.08, P > 0.05), 
PCL and β-TCP scaffolds cultured in osteogenic medium. 
At 14 days, significant differences in the cell proliferation in scaffolds cultured in growth 






Figure 14.  Cell proliferation on different scaffold types and time points.  *Represent significant 
differences in the total DNA content in hASC loaded to different scaffolds within the same time 








osteogenic – 15499.33±3524.02, P < 0.05) and PCL (control – 417911.33±10953.73; osteogenic 
– 254046.70±6564.63, P < 0.05) scaffolds.  Between scaffold types, cell proliferation was the 
highest in akermanite:PCL scaffolds cultured in both media conditions (control – 
535119.30±16157.50; osteogenic – 555045.30±12661.80, P > 0.05), followed, respectively, by 
PCL scaffolds cultured in control medium, PCL scaffolds cultured in osteogenic medium and β-
TCP scaffolds cultured in control medium.  At 14 days, the lowest cell proliferation was 
observed in akermanite (control – 20431.33±1731.71; osteogenic – 26918.67±988.60, P > 0.05) 
and β-TCP scaffolds cultured in osteogenic medium.  
At 21 days, significant differences in the cell proliferation in scaffolds cultured in growth 
(control) and osteogenic media were observed only in hASC loaded to β-TCP (control – 
196960.30±35467.99; osteogenic – 51252.67±1510.23, P < 0.05) scaffolds.  Between scaffold 
types, cell proliferation was the highest in akermanite:PCL scaffolds cultured in both media 
conditions (control – 287820.30±62987.16; osteogenic – 442140.30±11247.61, P > 0.05),  
followed by comparable levels in β-TCP scaffolds cultured in control medium and PCL (control 
– 207037.33±13518.60; osteogenic – 206693.37±15442.30, P > 0.05) which were significantly 
higher than β-TCP scaffolds cultured in osteogenic medium.  After 21 days, the lowest cell 
proliferation was again observed in akermanite scaffolds (control – 21174.67±2487.99; 
osteogenic – 15243.33±1475.49, P > 0.05).  
3.3.5. Quantitative Real-Time Polymerase Chain Reaction (QPCR) 
The differences in the expression of ALP (A) and OCN (B) in hASC loaded to different 
scaffolds and cultured in control and osteogenic media are represented in Figure 15.  In general, 
the ALP fold change significantly decresead overtime in all scaffold tested, with the exception of 
PCL which had comparable ALP fold change at 7 (16.38±4.98) and 14 (12.00±2.39) days of 
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culture.  At 7 days, the highest ALP fold change was observed in hASC loaded to akermanite 
scaffolds (83.61±4.97) which was followed by comparable ALP fold change in PCL, 
akermanite:PCL (15.29±0.85) and β-TCP (10.57±0.67) scaffolds.  After 14 days, the ALP fold 
change was the highest in akermanite (19.48±5.69), followed by PCL which was significantly 
higher than the ALP fold change observed in β-TCP (3.27±0.35) and akermanite:PCL 
(2.90±3.24) scaffolds.  At 21 days, the highest ALP fold change was observed in hASC loaded to 
akermanite scaffolds (8.81±4.40), followed by PCL (0.75±0.09) and β-TCP (0.68±0.48) 
scaffolds which were significantly higher the ALP fold change observed in akermanite:PCL 
(0.02±0.01) scaffolds.  
The OCN fold change in hASC loaded to different scaffolds and cultured in control and 
osteogenic media significantly increased overtime in all scaffold tested, with the exception of  
PCL which had comparable OCN fold change at 7 (2.69±0.88) and 14 (3.28± 0.10) days of 
culture.  At 7 days, the highest OCN fold change was observed in hASC loaded to akermanite 
scaffolds (11.67±1.93) which was significantly higher than comparable OCN fold change in 
akermanite:PCL (3.05±0.33), PCLand β-TCP (1.53±0.43) scaffolds.  After 14 days, the OCN 
fold change was the highest in akermanite (20.94±1.79) and akermanite:PCL (16.33±8.47) 
scaffolds, followed by β-TCP (9.19±2.73) which was significantly higher than the OCN fold 
change in PCL scaffolds.  At 21 days, the highest OCN fold change was observed in  
hASC PCL which had comparable OCN fold change at 7 (2.69±0.88) and 14 (3.28± 0.10) days 
of loaded to akermanite scaffolds (372.32±33.78), followed by akermanite:PCL (100.90±0.77) 
which was significantly higher than the OCN fold change observed in β-TCP (15.22±3.41) 
scaffolds.  After 21 days, the lowest OCN fold change was observed in hASC loaded to PCL 













































Figure 15.  Fold change of ALP (alkaline phosphatase) and OCN (osteocalcin) in hASC loaded 
to different scaffold types and cultured conditions (control and osteogenic) for a 21 days period.  






A suitable scaffold for bone regeneration must allow for high density cell attachment, 
proliferation, and ultimately support in vivo bone regeneration with degradation rate largely 
matched to the rate of cell ingrowth and mineralization(Gaalen et al., 2008).  Additionally, 
current paradigms also describe some other desirable properties, such as the easy-of-use of bone 
scaffolds during surgical implantation and the scaffolds mechanical properties (Reichert & 
Hutmacher, 2011).  Among the bioactive glass-ceramics, akermanite (Ca2MgSi2O7) can enhance 
cell adhesion, proliferation and osteogenesis while providing predictable and controllable 
degradation rate (Sun et al., 2006; Wu et al., 2006ab; Wu et al., 2007; Huang et al., 2009; Gu et 
al., 2011). However due to the brittle behavior of akermanite, pure scaffolds are difficult to use, 
adding complexity to the clinical translation of this technology(Kneser et al., 2006; Gaalen et al., 
2008; Reichert & Hutmacher, 2011).  In our previous study, we developed a novel 
akermanite:PCL composite as a potential moldable scaffold for future bone tissue engineering 
applications.  As part of the in vitro characterization of this material, we now report the 
osteogenic potential of hASC loaded to akermanite:PCL scaffolds and cultured in growth 
(control) or osteogenic media for 21 days.  In summary, after 21 days of culture in both media 
conditions, the hASC metabolic activity and proliferation in akermanite:PCL scaffolds were 
similarly decreased but inversally proportional to the calcium deposition and expression of 
mature osteogenic marker (OCN) observed in akermanite:PCL scaffolds cultured in osteogenic 
medium.  
The ideal scaffolds materials for bone tissue engineering should be bioactive.  The bioactivity 
of the bone tissue engineering scaffolds contributes to their capability for forming an apatite-like 
layer when they are in contact with physiological fluids (Sun et al., 2006; Liu et al., 2008; Gu et 
96 
 
al., 2011).  Previous, the Ca, Mg and Si ions extracted from akermanite were demonstrated to 
facilitate the osteogenic differentiation of hASCs via an ERK pathway, and suppress the 
metabolic acitivity and proliferation of hASCs without significant cytotoxicity (Gu et al., 2011).  
In this study, the decreased metabolic activity and proliferation observed in hASC loaded to pure 
akermanite scaffolds might also be the result of the cell proliferation suppression phenomenon 
demonstrated by Gu et al. (2011).  Compared to pure akermanite scaffolds, hASC loaded on 
akermanite:PCL scaffolds and cultured in different media conditions had higher metabolic 
activity and cell proliferation.  The media treatments used in this study influenced the metabolic 
activity of hASC loaded to akermanite:PCL scaffolds without significant changes in cell 
proliferation only within the first 7 days of culture.  After 14 days, hASC metabolic activity and 
proliferation were increased in akermanite:PCL scaffolds but no differences between the media 
conditions were observed.  At 21 days, the metabolic activity and proliferation of hASC in 
akermanite:PCL scaffolds were equally decreased in scaffolds cultured in both media conditions.   
Part of the changes observed in the metabolic activity and proliferation of hASC loaded to 
akermanite:PCL scaffolds described in this study might be due to the concentration of 
akermanite in the composite scaffolds.  According to the findings observed in pure akermanite 
scaffolds (Gu et al, 2011), suppression of DNA synthesis and cell division might had been 
initially delayed in hASC loaded to the akermanite:PCL scaffolds because, in this study, 
significant reductions in the hASC metabolic activity and proliferation were reported only after 
21 days.  Alternatively, it is well established that in aqueous environments, synthetic apatites 
degrade overtime through physiochemical dissolution and, possibly, phase transformation.  
Depending on the concentration of the biomaterial this may result in decreased biocompatibility 
(Bouler et al., 2000; Chen et al., 2008; Chen et al., 2010).  Additionally, PCL is also known to 
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release caproic acid, which at high concentration can produce cytotoxic effects (Sarasam et al., 
2007).  Therefore, the changes observed after 21 days in the metabolic activity and proliferation 
of hASC loaded to akermanite:PCL scaffolds could had also been the result of increase phase 
transformation and release of caproic acid.  However, even though hASC loaded to β-TCP 
scaffolds had higher metabolic activity than the observed in akermanite:PCL scaffolds after 21 
days, cell proliferation in akermanite:PCL scaffolds was significantly higher than in β-TCP 
scaffolds.  Moreover, after 21 days, both parameters were significantly higher in hASC loaded to 
akermanite:PCL scaffolds than in PCL scaffolds.  As a result, the changes observed in this study 
in the metabolic activity and proliferation of hASC loaded to akermanite:PCL scaffolds seems to 
be related to the akermanite concentration rather than scaffold phase transformation or polymer 
breakdown.  Further investigations are needed to characterize the influence of bioactive scaffolds 
on the hASC metabolic activity and proliferation.  
Progression of in vitro osteogenesis is characterized by decreased cellular proliferation 
followed by increased amounts of calcium deposition over time (Hirano & Urist, 1981; Bauer & 
Muschler, 2000; Milat & Wah, 2009).  In this study, decreased metabolic activity and cell 
proliferation were inversally proportional to the increased calcium deposition and expression of 
osteogenic markers.  Moreover, calcium deposition was significanlty higher in akermanite and 
akermanite:PCL scaffolds cultured in both media conditions than in β-TCP and PCL scaffolds.  
Osteogenesis is known to be regulated by bone morphogenic proteins (BMPs) which have been 
reported to stimulate the transcription factor core binding factor alpha1 (Cbfa1) by activating 
osteoblast-specific genes such as ALP and OCN through the binding to the osteoblast-specific 
cis-acting element 2 (OSE2) in the promoter region of these genes (Liu et al., 2008; Milat & 
Wah, 2009).  In this study, the ALP fold change between scaffolds cultured in control and 
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osteogenic media significantly decreased overtime.  Alkaline phosphatase is an early stage 
marker for osteogenic differentiation (Gaalen et al., 2008; Gu et al., 2011) and, together with 
OCN it is part of rapid and robust osteogenic differentiation (Liu et al., 2008; Milat & Wah, 
2009; Gu et al., 2011).  Therefore, the results presented in this study, indicated that hASC loaded 
to akermanite or akermanite:PCL scaffolds or cultured in osteogenic medium had increased 
osteogenic differentiation and osteoblast maturation during the course of this study.  Further 
investigations are needed to demonstrate the expression of proteins associated with these or other 
osteogenic markers.  
In summary, this study demonstrated that hASC loaded to akermanite:PCL scaffolds have 
calcium deposition greater than β-TCP and PCL control scaffolds.  Moreover, the expression of 
the mature osteoblast maker (OCN) in hASC loaded to akermanite:PCL scaffolds cultured in 
osteogenic medium was signifincantly higher than the observed in β-TCP and PCL scaffolds 
after 21 days.  Further investigations are needed to investigate if cryopreservation of hASC 
loaded to akermanite:PCL scaffolds  influence the in vitro viability and osteogenic differentiation 
potential of the hASC. 
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Chapter 4. Freezing Response and Optimal Cooling Rates of Human Adipose-Derived 
Stem Cells Loaded to Akermanite:Poly-E-Caprolactone Bone Scaffolds 
4.1. Introduction 
Tissue engineering scaffolds have recently emerged as potent substitutes to autologous and 
allogenous grafts in bone fracture repair strategies (Reichert & Hutmacher 2011).  In part this 
success is due to the fact that bone scaffolds composed of different biomaterials have been 
demonstrated to promote bone growth by supporting cell migration, proliferation and 
differentiation in the fracture site (De Girolamo et al., 2008; Jeon et al., 2008; Ahn et al., 2009).  
Additionally, the utilization of donor adult stem cells in combination with bone scaffold 
materials has emerged as a potential therapeutic modality for musculoskeletal repair (Gimble et 
al., 2010).  Among the adult stem cells sources used in current bone scaffold tissue engineering 
strategies, human adipose-derived stem cells (hASC) represent a readily available, autogenous 
cell source with well-documented in vivo osteogenic potential (Gaalen et al., 2008; Gimble et al., 
2011).  One of the foreseeable challenges to the clinical application of combination hASC-
scaffold therapies is the lack of a predictable shelf life for cell/scaffold combinations (Gaalen et 
al., 2008; Reichert & Hutmacher 2011).  With the growing interest in this therapeutic modality, 
methods of cryopreservation for stem cells on scaffolds that maintain the cell’s differentiation 
potential and scaffolds may become an urgent need.  Therefore, understanding the freezing and 
post-thaw characteristics of scaffold materials loaded with hASC could be essential. 
The goal of any cryopreservation protocol is to minimize ultrastructural damage related to 
sudden intracellular or extracellular ice crystal formation (Thirumala et al., 2005; Goh et al., 
2007).  One advantage of the development of cryopreservation methods for synthetic scaffold-
cell combinations compared to living tissue is that, depending on the scaffolding material, 
cryopreservation is unlikely to interfere with the morphological structure and architecture of the 
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construct, both vital for the post-thaw mechanical support and the biological function of the 
loaded cells (Kuleshova & Hutmacher 2008).  Of the current cryoprotectants used in 
combination with hASC, polyvinylpyrrolidone (PVP) is a Food and Drug Administration (FDA) 
approved high molecular weight cryoprotectant agent that has been shown to enhance hASC 
viability and differentiation in vitro (Guha & Devireddy 2010; Thirumala et al., 2010a; 
Devireddy & Thirumala 2011).  While PVP activity is not entirely understood, it is believed that 
PVP favorably influence the ice crystal formation in hASC by altering the physical properties of 
the solution during the freezing cycle (Thirumala et al., 2010a).  Moreover, raised awareness of 
the potential for zoonotic disease transmission through bovine serum supplementation has 
resulted in an alternative PVP serum-free medium protocol for hASC cryopreservation 
(Thirumala et al., 2010b).  Based on this information, PVP-based cryopreservation in serum-free 
medium might also be beneficial for cryopreservation of donor hASC on scaffolds.  However, 
many fundamental questions related to the hASC-scaffold response to different cooling rates still 
remain to be investigated before an optimal scaffold freezing protocol can be developed. 
Therefore the objective of this study was to compare cell viability, proliferation and 
osteogenic differentiation of hASC loaded to a bone scaffold composites made of 
akermanite:poly-e-caprolactone (PCL) under different cooling rates.  The hypothesis of this 
study was that compared to unfrozen scaffolds (controls), cell-scaffold combinations frozen at 
optimal cooling rate would display similar or improved metabolic activity, cell proliferation and 






4.2. Materials and Methods 
4.2.1. Synthesis of Akermanite 
Akermanite, Ca2MgSi2O7, was synthesized by ceramic methods with calcium carbonate 
(1.237 g, 12.4 mmol), magnesium carbonate (0.521 g, 6.2 mmol), and silicon dioxide (0.742 g, 
12.4 mmol) as the starting materials.  These materials were mixed and ground up thoroughly 
using an agate mortar and pestle.  The 2.5 g white powder mixture was then pressed into a pellet 
with hydraulic press (with approximately 1 metric ton of applied pressure) and then heated up 
multiple times in an open to air boat-shaped alumina crucible using a programmable box furnace 
to achieve the following net reaction: 
2 CaCO3 + MgCO3 + 2 SiO2 → Ca2MgSi2O7 + 3 CO2 (g) 
The initial heat treatment was carried out at 950°C (after increasing the furnace chamber 
temperature from room temperature at rate of 100°C/h) for 48 hours.  This intermediate reaction, 
which involves the conversion of the carbonate starting materials to oxides, was then allowed to 
cool down back to room temperature by heat loss through the top exhaust port of the furnace.  
The pellet was then weighed to confirm the mass loss of approximately 0.8 g (or 18.5 mmol) of 
carbon dioxide.  Subsequent heat treatments involved additional grinding, pellet pressing, and 
heating the crude product at the dwell temperature of 1300°C (after ramping up the temperature 
from room temperature at rate of 100°C/h) for 48 hours.  Each 48 hour heat treatment was 
followed by cooling back to room temperature by furnace exhaust.  The number of heat 
treatments at 1300°C required was dictated by proof of desired product purity (as judged by 





4.2.2. Fabrication of Akermanite:PCL Scaffolds 
A 10% PCL solution in 8 ml of 1-4, dioxane was prepared and akermanite was added at 
weight (g) ratio of 0.6:0.2 (akermanite:PCL) in a glass bottle.  The mixtures were molded into 
10mmX4mm polydimethylsiloxane (PDMS) templates, frozen at -80ᵒC overnight and 
immediately incubated in a freeze-drier for 48 hours.  Dried akermanite:PCL scaffolds were 
prepared for viability and osteogenic studies.  
4.2.3. Isolation of hASC and Culture 
Liposuction aspirates from subcutaneous adipose tissue were obtained from male (n = 1) and 
females (n = 2) subjects undergoing elective procedures.  All tissues were obtained with 
informed consent under a clinical protocol reviewed and approved by the Institutional Review 
Board at the Pennington Biomedical Research Center.  Isolation of hASC was performed as 
described elsewhere (Gimble et al., 2011). The initial passage of the primary cell culture was 
referred to as ‘‘Passage 0’’ (p0).  The cells were passaged after trypsinization and plated at a 
density of 5,000 cells/cm
2
 (‘‘Passage 1’’) for expansion on T125 flasks until 80% of confluence 
was reached.  Passage 2 of each individual was used for all analysis. 
4.2.4. hASC Loading on Scaffolds and Culture 
Passage 2 of each donor (n = 3) was loaded to each scaffold using a custom-made spinner 
flask bioreactor at loading density of 2,500 cells/mL for 2 hours.  Immediately after, 6 scaffolds 
were transferred into 6-well plates (1 scaffold/well) and maintained in DMEM + 10% PVP for 
20 min and immediately collected for analysis or cultured in stromal medium for 10 days with 
weekly data collection (controls).  The remaining scaffolds (n = 34) were frozen at cooling rates 
of 1ᵒC/min, 2ᵒC/min, 5ᵒC/min, 10ᵒC/min and 40ᵒC/min.  Immediately after, the scaffolds were 
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thawed in a water bath incubated at 37ᵒC and collected for analysis (time point 0) or cultured in 
stromal medium for 10 days.   
4.2.5. Detection of Cell Viability with Alamar Blue Staining 
The metabolic activity of cells within the scaffolds immediately after thawing (time point 0) 
and at 10 days in stromal medium was determined with the Alamar Blue™ assay.  The scaffolds 
were removed from culture, washed three times in PBS, and incubated with 10% Alamar Blue™ 
in Hank’s balanced salt solution (HBSS) without phenol red (pH 7) for 90 min.  Aliquots (100 
μL) of Alamar Blue™/HBSS were placed in a 96-well plate in triplicate, and the fluorescence 
was measured at an excitation wavelength of 530 nm and an emission wavelength of 595 nm 
using a fluorescence plate reader.   
4.2.6. Alizarin Red Staining 
hASC osteogenesis at time point 0 and after 10 days of culture was assessed with alizarin 
red.  Briefly, scaffolds were washed with 0.9% NaCl (1 ml/well) and fixed with 70% ethanol (1 
ml/well).  Subsequently, the fixative was removed by aspiration and plates were stained with 2% 
alizarin red for 10 min and washed with deionized water.  The scaffolds were destained by the 
addition of 2 ml of 10% cetylpyridinium chloride monohydrate to each well followed by shaking 
for 10 min at room temperature.  The calcium deposition expressed by the optical density of the 
aliquots was then measured at 540 nm with a plate reader.  
4.2.7. Quantification of DNA on Scaffolds
 
Total DNA content was used to determine the number of cells on each scaffold as previously 
described (Liu et al., 2008).  Briefly, scaffolds were crushed and then incubated with 0.5 mL 
proteinase K (0.5 mg/mL) at 56ºC overnight.  The mixture was centrifuged at 108g for 5 minutes 
and then 50 µl aliquots were mixed with 50 µl Picogreen dye solution (0.1 g/mL, Invitrogen) in 
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96-well plates.  Samples were excited at 480 nm and total DNA concentration was compared to a 
standard curve generated from serial dilutions of hASC.  Scaffold without cells were used to 
subtract the background fluorescence emission from all readings. 
 
4.2.8. Quantitative Real-Time Polymerase Chain Reaction (QPCR)
 
Total RNA was extracted from cells and cell-scaffolds using the Trizol reagent (Sigma).  
QPCR was performed using 2X iTaq SYBR green with ROX (Biorad) and alkaline phosphatase 
(ALP) forward (5’- AATATGCCCTGGAGCTTCAGAA -3’) and reverse (5’- 
CCATCCCATCTCCCAGGAA -3’) and osteocalcin (OCN) forward (5’- 
GCCCAGCGGTGCAGAGT -3’) and reverse (5’- TAGCGCCTGGGTCTCTTCAC -3’) to 
assess the osteogenic differentiation of hASC loaded to scaffolds immediately after thawing and 
at 10 days of culture.  Reactions were performed with a MJ Mini Thermal Cycler (BioRad).  
Water (negative) and hASC culture in osteogenic medium for 14 days were used as controls.  
Samples were normalized (ΔCt) against the house keeping gene 18SrRNA.   
4.2.9. Micro-Computer Tomography (μ-CT) at Optimal Freezing Rate 
Samples were aligned along their axial direction and stabilized with wet gauze in a 1.5 mL 
centrifuge tube. The tubes were clamped in the specimen holder of a SkiscanCT1074 system 
(Skiscan, Belgium).  The pixel value in two-dimensional images were used to calculate the 
deposition of bone on the scaffolds after 10 days.  
4.2.10. Statistical Analysis 
All results were expressed as mean±SEM.  Normality of the data was confirmed using the 
Shapiro-Wilk test (P < 0.001).  Data was analyzed with one or two-way analysis of variance 
(ANOVA), followed by Tukey’s minimum significant difference (MSD) post hoc test for 
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pairwise comparisons of main effects.  For all comparisons, a P-value < 0.05 was considered 
significant. 
4.3. Results 
4.3.1. Cell Viability 
The metabolic activity of hASC loaded to akermanite:PCL scaffolds significantly differed 
between fresh and frozen samples as shown in Figure 16A.  At time point 0, comparable 
metabolic activity expressed by the Alamar blue stain was observed in scaffolds frozen at 1 and 5 
ᵒC/min (16469.92±174.42 and 15450.88±85.08, respectively), which were significantly greater 
than the metabolic activity in scaffolds frozen at 2 and 10ᵒC/min (14656.20±120.87 and 
14809.21±39.73, respectively).  Within this time point, the lowest metabolic activity of hASC 
loaded to akermanite:PCL scaffolds was observed in unfrozen scaffolds (control) 13386.30± 
595.13) and scaffolds frozen at 40ᵒC/min (13242.81±36.17).  However, after 10 days in stromal 
medium, hASC loaded to scaffolds frozen at 40 ᵒC/min had the highest metabolic activity 
(32752.86±126.43) which was followed by scaffolds frozen at 5ᵒC/min (21146.90±172.33, 1 
ᵒC/min (14331.37±165.29), 10ᵒC/min (12545.92±54.30) and 2ᵒC/min (11505.14±69.43), 
respectively, as depicted in Figure 16A.  At this time point, hASC loaded to control scaffolds 
(unfrozen) displayed the lowest metabolic activity (10145.12±72.47). 
4.3.2. Calcium Deposition 
Figure 16B depicts calcium deposition in fresh and frozen akermanite:PCL scaffolds loaded 
with hASC.  At time point 0, increased deposition of calcium measured by the alizarin red stain 
was observed in unfrozen (control) scaffolds (0.506±0.006) which was significantly greater than 
scaffolds frozen at 2ᵒC/min (0.4237±0.001), 1 and 40ᵒC/min (0.295± 0.017; 0.329±0.011, 
respectively).  At this time point, the lowest calcium deposition was observed in scaffolds frozen  
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at 5 and 10ᵒC/min (0.245±0.003; 0.235±0.015, respectively).  Following 10 days of culture in 
stromal medium, increased calcium deposition was observed in scaffolds frozen at 40ᵒC/min 
(3.611±0.018), with reduced calcium deposition being found in scaffolds frozen at 1ᵒC/min 
(2.017±0.009), 2ᵒC/min (1.488±0.013), control and 10ᵒC/min (1.353±0.003; 1.335±0.007).  At 
this time point, hASC loaded to scaffolds frozen at 5ᵒC/min displayed the lowest calcium 
deposition (1.044±0.009).  
4.3.3. Quantification of DNA on Scaffolds 
The loading efficiency of the scaffolds after 2 hours of incubation in the spinner flask 
averaged 60% (60.23±0.03).  Total DNA content on fresh and frozen scaffolds significantly 
differed as represented in Figure 17.  At time point 0, total DNA was the highest in scaffolds 
frozen at 1 or 5ᵒC/min (39248.00±5616.81; 32000.00±355.67, respectively), followed by 
comparable values in control scaffolds (24057.33±1116.15) and scaffolds frozen at 2 and 
40ᵒC/min (22213.33±244.50; 21662.670± 2022.79, respectively).  Within this time point, total 
DNA was the lowest in scaffolds frozen at 10ᵒC/min (2500±538.65). After 10 days, total DNA 
was the highest in control scaffolds (79954.66±3167.46), followed by comparable values in 
scaffolds frozen at 10 and 40ᵒC/min (49572.00±899.07; 56248.00± 2911.30, respectively) which 
were significantly greater than scaffolds frozen at 1 or 2ᵒC/min (38833.33± 3574.86; 
40798.67±1257.84) and 5ᵒC/min (3904.00± 367.746). 
4.3.4. Quantitative Real-Time Polymerase Chain Reaction (QPCR) 
Quantitative data indicated that freezing significantly influenced the ALP expression at time 
point 0 (Figure 18A).  With the exception of fresh scaffolds (control), ALP expression was  
upregulated in all scaffolds.  Increased ALP mRNA expression immediately after scaffolds 








Figure 16. Metabolic activity (A) and calcium deposition (B) in fresh and frozen 
akermanite:PCL scaffolds loaded with hASC.  Lowercase letters indicate significant differences 
between the cooling rates within each time point (Tukey’s test, P < 0.05). 
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13.09± 5.20, respectively) which were significantly greater than the ALP expression observed in 
scaffolds frozen at 1 or 2ᵒC/min (1.95±0.34; 2.57±1.64, respectively).  After 10  
days, ALP expression was comparable in scaffolds frozen at 1, 2 or 40ᵒC/min (16.43±3.27; 
19.24±3.76; 15.69±1.97, respectively) which were significantly greater than scaffolds frozen at 5 
or 10ᵒC/min (2.24± 0.80; 2.03±0.83, respectively). 
Upregulation of the mature osteoblast marker OCN was observed only after 10 days of 
culture in scaffolds frozen at different cooling rates (Figure 18B).  Increased OCN mRNA 
expression was significantly greater in scaffolds frozen at 2, 5 or 10ᵒC/min (9.28±0.77; 
13.06±5.14; 11.38±3.25, respectively) than scaffolds frozen at 1 or 40ᵒC/min (4.68±1.99; 
2.45±1.56, respectively).  
4.3.5. Live/Dead staining at Optimal Freezing Rate 
hASC loaded to akermanite:PCL scaffolds and frozen at 2 and 40ᵒC/min were stained with 
Live/Dead stain after 10 days of culture to compare the number of viable cells post-culture to the 
observed in control (uncooled) scaffolds.  Figure 19 indicates that after 10 days of culture, 
scaffolds frozen at 40ᵒC/min had number of viable hASC similar to control scaffolds.  Live 
hASC were also observed in scaffolds frozen at 2ᵒC/min but compared to control or scaffolds 
frozen at 40ᵒC/min that number was much lower. 
4.3.6. Bone Deposition at Optimal Freezing Rate 
The radiodensity of control and scaffolds frozen at 2 and 40ᵒC/min changed after 10 days of 
culture (Figure 20).  In general, the highest bone deposition was observed in control 
(68026±35853) and scaffolds frozen at 40ᵒC/min (66478±6754) which were comparable but 








Figure 17.  Total DNA quantification on scaffolds.  Lowercase letters indicate significant 












































Figure 18. Relative mRNA expression of ALP (A – 0 and 10 days) and 
OCN (B – 10 days only) in scaffolds frozen at different cooling rates.  
Lowercase letters indicate significant differences between the cooling rates 




































































































































































































































































































































































































































































Adult stem cells cultured on composite scaffolds are emerging as the alternative method to 
regenerate bone in the 21
st
 century.  As freshly collected adult stem cells are not always readily 
available, there will be a need for improved cryopreservation methods to reproducibly maintain 
viability and osteogenesis of stem cells loaded to the scaffolds during long-term storage.  The 
objective of this work was to assess the effect of freezing on the metabolic activity and 
osteogenesis of hASC loaded to akermanite:PCL scaffolds and frozen in 10% PVP at different 
cooling rates in the absence of serum and other cryoprotective agents.  According to the results, 
the metabolic activity and DNA content of hASC in post-thaw scaffolds were the highest in 
scaffolds frozen at 1 and 5ᵒC/min, however significant differences in hASC osteogenesis were 
observed across the treatment groups.  While increased calcium deposition was observed in post-
thawed control (uncooled) scaffolds, the expression of an early marker for osteogenesis (ALP) 
was the highest in scaffold frozen at 5, 10 and 40ᵒC/min.  Moreover, after 10 days of culture in 
stromal medium, the metabolic activity and osteogenic differentiation of hASC-scaffolds frozen 
at different cooling rates were greater than in control (uncooled) scaffolds.  In summary, this 
study demonstrated that DMEM+PVP can be used to cryopreserve hASC loaded to 
akermanite:PCL bone scaffolds.  The data also suggested that freezing contributed to the hASC 
differentiation on the scaffolds.   
As cell attachment to scaffolds is a critical aspect of cell-assisted bone tissue engineering 
cryopreservation of scaffolds loaded with adult stem cells is dependant on the seeding technique 
applied  (Lawrence and Madihally 2010; Reichert & Hutmacher 2011).  Therefore, an easy to 
use high throughput method that allows a fast and homogeneous cell delivery before scaffold 
freezing will be preferred in future research or clinical strategies (Lawrence and Madihally, 
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2010).  In this study, a custom-made spinner flask was used to load hASC to akermanite:PCL 
scaffolds.  In principal, the technique relies on fluid convection and collision with the 
immobilized scaffolds to improve cell attachment and distribution throughout the scaffolds 
(Griffon et al., 2010).  Even though, the spinner flask used in this study yielded high cellular 
adherence in both control and post-thawed scaffolds, significant differences in the DNA content 
across both groups and time points were observed.  Such differences might be the result of 
differences in initial loading efficiency between scaffolds within the same spinner flask, the post-
freezing effect in scaffolds cultured for 10 days or losses associated with the DNA extraction 
protocol used in this study.  Nevertheless, Live/Dead (control; and scaffolds frozen at 2ᵒC/min 
and 40ᵒC/min) staining revealed an increased number of cells on the surface of the scaffolds after 
10 days of culture, indicating that with prolonged culture time (i.e., 8 weeks post-implantation) 
an increased number of viable cells, and therefore, bone growth, would be observed in the 
scaffolds.  While this assumption remains to be tested in vivo, nearer term in vitro studies are 
needed to optimize the concentration of cells on scaffolds before cryopreservation.  
Bone scaffolds should mimic, as closely as possible, the natural bone architecture to ensure 
cell attachment and migration within the porous materials.  More important, they should degrade 
or be integrated with the surrounding tissue and eventually be replaced by new or existing host 
tissue overtime (Gaalen et al., 2008).  Therefore, the bioactivity and slow degradation is highly 
desirable in scaffold-assisted bone healing.  In this study, hASC were loaded to akermanite:PCL 
scaffolds before cryopreservation.  Akermanite (Ca2MgSi2O7), is a bioactive glass ceramic with 
controllable degradation rate and desirable mechanical and biological properties previously 
shown to enhance hASC biocompatibility and osteogenesis in vitro (Liu et al., 2008; Gu et al., 
2011).  Poly-e-caprolactone (PCL) is an aliphatic polyester, poorly water-soluble that has a slow 
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degradation in vivo (Fabbri et al., 2010).  Due to the PCL melting temperature close to 
physiologic body temperature, current bone tissue engineering paradigms seek the utilization of 
PCL as a moldable scaffolding material (Leong et al., 2008; Fabbri et al., 2010).  As both 
Akermanite and PCL have well described biocompatibility and osteogenic qualities we sought to 
develop a novel composite scaffold (akermantie:PCL) combining the desirable properties of both 
biomaterials.   
Several studies investigated akermanite biocompatibility and osteogenesis with adult stem 
cells (Sun et al., 2006; Liu et al., 2008; Gu et al., 2011).  In general, akermanite has been shown 
to be highly biocompatible when combined with adult stem cells.  Moreover, hBMSC (human 
bone marrow-derived stem cells) and hASC proliferation on the surface of akermanite scaffolds 
has been reported to improve overtime (Sun et al., 2006; Liu et al., 208).  However, these 
previous studies assessed hASC osteogenesis and metabolic activity (biocompatibility) in the 
absence of a cryopreservation and thaw cycle.  In this study, Alamar blue stain was used to 
quantitate the metabolic activity of hASC loaded akermanite:PCL scaffolds frozen at different 
cooling rates.  The data indicates that, compared to control (uncooled) scaffolds, increased 
metabolic activity was observed in post-thawed scaffolds frozen at 1 and 5ᵒC/min.  But after 10 
days of culture in stromal medium, scaffolds frozen at 40ᵒC/min displayed remarkably greater 
hASC metabolic activity.  On the other hand, significant differences in hASC osteogenesis were 
observed across the group treatments.  While increased calcium deposition was observed in post-
thawed control (uncooled) scaffolds, the ALP expression was the highest in scaffold frozen at 5, 
10 and 40ᵒC/min.  Moreover, after 10 days of culture, scaffolds frozen at 40ᵒC/min had the 
highest calcium deposition and up-regulation of ALP and OCN (marker for mature osteoblasts).    
Even though, OCN expression in scaffolds frozen at 40ᵒC/min was significantly lower than in 
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scaffolds frozen at 2, 5 or 10ᵒC/min, μ-CT comparisons between scaffolds frozen at 40ᵒC/min 
and 2ᵒC/min and cultured for 10 days in stromal medium revealed significant increases in 
mineralization in scaffolds frozen at 40ᵒC/min.  Polyvinylpyrrolidone (PVP) might have 
influenced, in part, the hASC metabolic activity and osteogenesis in both control and post-
thawed scaffolds (Guha & Devireddy 2010; Devireddy & Thirumala 2011).  However, after 10 
days of culture, increased metabolic activity and osteogenesis was observed in scaffolds frozen 
using the most rapid cryopreservation protocol (40ᵒC/min).  While interesting, the mechanism 
underlying these results remain to be investigated.  The authors hypothesize that the combined 
akermanite bioactivity (Sun et al., 2006; Liu et al., 2008; Gu et al., 2011) and the favorable PVP 
influence in the nucleation process during the freezing cycle (Thirumala et al., 2010a) might play 
a role in the increased metabolic activity of scaffolds frozen at 40ᵒC/min.  Mechanical damage 
related to the scaffold from thermal expansion may result in higher concentrations of calcium, 
magnesium and silicon ions being released from the scaffold into the cell’s local 
microenviroment contributing to osteogenic potential. Alternatively, mechanical stresses 
imposed by the scaffold on the cells during freezing and thawing may modulate differentation. 
Future investigations will further assess these assumptions, partiularly, in hASC loaded to other 
bioactive scaffold materials.  
As a conclusion, this study demonstrated that akermanite:PCL scaffolds loaded with hASC 
can be cryopreserved with 10% PVP in serum-free medium.  Moreover, after 10 days of culture, 
optimal hASC metabolic activity and osteogenesis were observed in scaffolds initially frozen at 
40ᵒC/min.  However, before this protocol can be adapted for the preservation and preparation of 
cell-scaffold therapies further investigations are needed to elucidate the mechanisms of scaffold 
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Chapter 5. In Vivo Evaluation of Five Bone Substitute Scaffolds for Human Adult 
Mesenchymal Stem Cell Osteogenesis 
5.1. Introduction 
The engineering of osteogenic bone substitute grafts based on scaffolds loaded with human 
adult mesenchymal stem cells offers an attractive opportunity for the replacement of 
posttraumatic bone loss, treatment of delayed or non healing fractures or fusion of degenerated 
joints (Gaalen et al., 2008; Reichert & Hutmacher, 2011).  The concept has the potential to 
overcome the main limits associated with autologous and allogeneic bones, currently the golden 
standard bone grafts, namely donor site morbidity (Arrington et al., 1996; Ahlmann et al., 2002) 
and reduced availability (Boden, 2000) as well as time consuming bone banking procedures 
(Bauer & Muschler, 2000) and the risk for disease transmission (Reichert & Hutmacher, 2011).  
Among the biomaterials currently used in bone scaffold strategies, bioactive ceramics and highly 
purified polymers are the most common (Hattori et al., 2004; Scherberich et al., 2007; Dégano et 
al., 2008; De Girolamo et al., 2008; Liu et al., 2008; De Girolamo et al., 2009; Haimi et al., 
2009; Haimi and Suuriniemi, 2009; Haimi and Gorianc, 2009; Gastaldi et al., 2010; Marino et 
al., 2010; Muller and Mehrkens, 2010; Wang et al., 2010; Lee and Lee, 2011).  Particularly, 
because of their predictable manufacturing procedures which make both biomaterials easily 
processed for a variety of clinical/research bone tissue engineering applications (Gaalen et al., 
2008).  However, an ideal scaffolding material for in vivo cell-assisted bone formation 
independent of the donor stem cell source still remains to be identified.  
Several studies have indicated that the presence of a mineral biomimetic phase, such as 
hydroxyapatite (HA) or β-tricalcium phosphates (β-TCP), is important for the success of a 
scaffold promoting bone regeneration (De Girolamo et al., 2008; Marino et al., 2010; Muller and 
Mehrkens, 2010).  HA is more stable, exhibiting much lower dissolution rates (De Girolamo et 
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al., 2008; Gaalen et al., 2008; Muller and Mehrkens, 2010), whereas β-TCP is more soluble and 
its degradation products, calcium and phosphate, are released into the surrounding environment, 
potentially inducing bioactivity (Bouler et al., 2000; Gaalen et al., 2008; Liu et al., 2008; Marino 
et al., 2010).  More recently, silica-based glass ceramics, such as akermanite, has been also 
observed to promote bone growth (Sun et al., 2006; Wu et al., 2006ab; Wu et al., 2007; Huang et 
al., 2009; Gu et al., 2011).  Compared to HA and β-TCP, porous akermanite scaffolds have 
enhanced mechanical and bioactivity properties (Agathopoulos et al., 2005; Wu et al., 2006a; 
Chen at al., 2010).  Moreover, due to the ability to form apatite-like layers at a physiological 
fluid interface, akermanite scaffolds have been shown to enhance cell adhesion, proliferation, 
osteogenic differentiation, and extracellular matrix mineralization in vitro (Sun et al., 2006; Liu 
et al., 2008; Gu et al., 2011).  However, independent of the bioceramic used, the native 
brittleness of current ceramic scaffolds make translation to clinical setting difficult (Kneser et al., 
2006; Reichert & Hutmacher, 2011).   
In contrast, many synthetic biodegradable polymers are proposed in various tissue 
engineering applications, including bone tissue repair, based on their flexibility of material 
properties and the ability to support cell growth (Hattori et al., 2004; Dégano et al., 2008; Wang 
et al., 2010; Lee and Lee, 2011).  Poly-e-caprolactone (PCL) is one of the most versatile 
synthetic polymers used today (Leong et al., 2006; Leong et al., 2008; Zhang et al., 2009).  Due 
to its biocompatibility, poor water solubility, melting point close to physiologic body 
temperature and slow in vivo degradation, PCL has been proposed as a composite moldable 
scaffolding material in many bone scaffold applications (Leong et al., 2006; Gaalen et al., 2008; 
Zhang et al., 2009; Fabbri et al., 2010).  However, in vivo osteogenic comparisons of pure PCL 
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to others commonly used bioceramic materials in the presence or absence of human adult 
mesenchymal stem cells isolated from different tissue sources remain to be investigated.  
Identification of a scaffolding material that display similar in vivo bone growth independent 
of the human adult mesenchymal stem cells source is appealing because it could facilitate 
comparisons between current in vivo protocols.  Due to the PCL recognized biological and 
mechanical properties, in this study, we compared the in vivo ectopic bone formation of pure 
porous PCL scaffolds to β-TCP and β-TCP:HA (CellCeramic
TM
) ceramic scaffolds in the 
presence or absence of human adipose-derived mesenchymal stem cells (hASC) and bone 
marrow-derived mesenchymal stem cells (hBMSC) 8 weeks post-implantation.  Additionally, we 
reported an acute phosphorous depletion toxicity associated with subcutaneous implantation of 
akermanite and akermanite:PCL scaffolds in immunodeficient mice.  
5.2. Materials and Methods 
5.2.1. Synthesis of Akermanite 
Akermanite, Ca2MgSi2O7, was synthesized by ceramic methods with calcium carbonate 
(1.237 g, 12.4 mmol), magnesium carbonate (0.521 g, 6.2 mmol), and silicon dioxide (0.742 g, 
12.4 mmol) as the starting materials.  These materials were mixed and ground up thoroughly 
using an agate mortar and pestle.  The 2.5 g white powder mixture was then pressed into a pellet 
with hydraulic press (with approximately 1 metric ton of applied pressure) and then heated up 
multiple times in an open to air boat-shaped alumina crucible using a programmable box furnace 
to achieve the following net reaction: 
2 CaCO3 + MgCO3 + 2 SiO2 → Ca2MgSi2O7 + 3 CO2 (g) 
The initial heat treatment was carried out at 950 °C (after increasing the furnace chamber 
temperature from room temperature at rate of 100 °C/h) for 48 hours.  This intermediate reaction, 
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which involves the conversion of the carbonate starting materials to oxides, was then allowed to 
cool down back to room temperature by heat loss through the top exhaust port of the furnace.  
The pellet was then weighed to confirm the mass loss of approximately 0.8 g (or 18.5 mmol) of 
carbon dioxide.  Subsequent heat treatments involved additional grinding, pellet pressing, and 
heating the crude product at the dwell temperature of 1300°C (after ramping up the temperature 
from room temperature at rate of 100°C/h) for 48 hours.  Each 48 hour heat treatment was 
followed by cooling back to room temperature by furnace exhaust.  The number of heat 
treatments at 1300°C required was dictated by proof of desired product purity (as judged by 
powder X-ray diffraction) and typically varied with each batch from 2 to 3 times. 
5.2.2. Synthesis of Ceramic Scaffolds  
Akermanite and β-tricalcium phosphate (β-TCP) powders (3 g) were suspended in polyvinyl 
alcohol aqueous solution (10 wt %) and stirred in a glass beaker to obtain a well-dispersed slurry 
(Liu et al., 2008).  Polyurethane foam templates were cut into the desired shape and sizes 
(5mmX4mm) to replicate a porous scaffold.  Then, the prepared templates were immersed in a 
glass beaker containing akermanite or β-TCP slurry and compressed with glass stick to force the 
slurry to migrate into the pores of the foams which were then incubated at 60°C for 1 day.  After 
drying, the scaffolded materials (either akermanite or β-TCP) were placed in an open to air boat-
shaped alumina crucible and heated up in a programmable box furnace from room temperature 
(at rate of 50°C/h) to 500°C and allowed to dwell this temperature for 5 hours in order to burn 
off the polyurethane foam.  After allowing the furnace to cool down to room temperature by 
furnace exhaust, the scaffolds were then heat treated at 1300°C (increasing the furnace chamber 




5.2.3. Fabrication of PCL and Akermanite:PCL Scaffolds 
Composites (akermanite:PCL) and pure PCL solutions were frozen at -80ᵒC overnight.  A 
10% PCL solution in 8 ml of 1-4, dioxane was prepared and akermanite was added at weight (g) 
ratio of 0,0:0,8 (PCL) and 0.6:0.2 (75:25 akermanite:PCL wt.%) in a glass bottle.  The mixtures 
were molded into 5mmX4mm polydimethylsiloxane (PDMS) templates and immediately 
incubated in a freeze-drier for 48 hours.   
5.2.4. Adult Stem Cells Isolation and Culture 
Liposuction aspirates from subcutaneous adipose tissue were obtained from male (n = 1) and 
females (n = 2) subjects undergoing elective procedures.  All tissues were obtained with 
informed consent under a clinical protocol reviewed and approved by the Institutional Review 
Board at the Pennington Biomedical Research Center.  Isolation of hASC was performed as 
described elsewhere (Gimble et al., 2011).  Briefly, tissues was washed 3–4 times with phosphate 
buffered saline and suspended in an equal volume of PBS supplemented with 1% bovine serum 
and 0.1% collagenase type I.  The tissues were placed in a shaking water bath at 37ᵒC with 
continuous agitation for 60min and centrifuged for 5min at 300–500g at room temperature.  The 
supernatant, containing mature adipocytes was then aspirated.  The cell pellet, referred to as the 
stromal vascular fraction (SVF), was suspended and plated immediately in T125 flasks in stromal 
medium at density of 0.156ml of tissue digest/cm
2
 of surface area for expansion and culture.  
Human bone marrow-derived stem cells (hBMSC) were isolated from the bone marrow of three 
females at Tulane University School of Medicine.  The initial passage of each adult stem cell 
type was referred to as ‘‘Passage 0’’ (p0).  The cells were passaged after trypsinization and 
plated at a density of 5,000 cells/cm
2
 (‘‘Passage 1’’) for expansion on T125 flasks until 80% of 
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confluence was reached.  Passage 2 of each individual and cell type was used for in vivo ectopic 
bone formation studies.  
5.2.5. hASC Loading on Scaffolds and Culture  
Passage 2 of each donor (n = 3) and adult stem cell type were pooled together and directly 
loaded on the top of each scaffold type at loading density of 5.0X10
4
 cells/5μL.  After 30 min of 
incubation at 37ᵒC and 5% CO2, the same process was repeated on the opposite top of each 
scaffold.  Experimental groups included: akermanite:PCL, akermanite, PCL, β-TCP and 
CellCeramic
TM
.  After overnight incubation at 37ᵒC and 5% CO2, scaffolds with or without each 
adult stem cells type were subcutaneously implanted in adult male immunodeficient (nude) mice 
[1 scaffold type (with and without cells)/mouse] with sample collection performed 8 weeks post-
implantation to assess ectopic bone formation (Figure 21).  
5.2.6. In vivo Implantation in Nude Mice  
Five adult male immunodeficient mice were divided in five groups (akermanite:PCL, 
akermanite, PCL, β-TCP and CellCeramic
TM
) for each stem cell type.  Animals were 
anesthetized with isofluorane.  Three incisions were made just dorsal to the midline of each 
animal and the subcutaneous pockets were made parallel to each side.  Scaffolds were implanted 
in the pockets (6 pockets per animal) and the skin incisions were apposed using stainless steel 
Michel clips.  Each mouse had one scaffold type (with and without cells) implanted into 
subcutaneous pockets (Figure 21).  Eight weeks post-implantation, PCL, β-TCP and 
CellCeramic
TM
 scaffolds were harvested immediately post-mortem following humane euthanasia 

























































































































































































































































































5.2.7. Effect of Ionic Dissolution of Akermanite and Akermanite:PCL Scaffolds  
The dissolution of akermanite and akermanite:PCL scaffolds 48 hours post-implantation was 
prepared by overnight nitric acid digestion.  The ratio of the akermanite and akermanite:PCL 
weight and the medium volume was 200 mg/mL.  The ionic concentration of calcium, 
magnesium, silicon and phosphorous on the akermanite and akermanite:PCL digests was 
measured by inductively coupled plasma spectroscopy (ICP-OES) as previously described (Wu 
et al., 2006b). 
5.2.8. Characterization of the Ionic Composition on the Surface of Akermanite and 
Akermanite:PCL Scaffolds 
 
The percentage of calcium, magnesium, silicon and phosphorous on the surface of 
akermanite and akermanite:PCL scaffolds 48 hours post-implantation was assessed with X-ray 
Photoelectron Spectroscopy (XPS) in a Kratos Axis-165 XPS/AES instrument (Kratos).  
5.2.9. Quantitative Real Time Polymerase Chain Reaction (QPCR)
 
Total RNA was extracted from cell-scaffolds (PCL, β-TCP and CellCeramic
TM
) using the 
Trizol reagent (Sigma).  QPCR was performed using 2X iTaq SYBR green with ROX (Biored) 
and osteocalcin (OCN) forward (5’- GCCCAGCGGTGCAGAGT -3’) and reverse (5’- 
TAGCGCCTGGGTCTCTTCAC -3’) to assess expression of mature osteogenic marker in hASC 
loaded to scaffolds 8 weeks post-implantation.  Reactions were performed with a MJ Mini 
Thermal Cycler (BioRad).  Water (negative) and hASC culture in osteogenic medium for 21 
days were used as controls.  Samples were normalized (ΔCt) against the house keeping gene 
18SrRNA and the fold change expression of OCN in scaffolds preloaded with adult stem cells 





5.2.10. Histological Analysis  
The constructs were washed in PBS and fixed in 10% formalin for 1 day, decalcified with 
immunocal solution (Decal Chemical) for 3 hours, dehydrated with graded ethanol washes, 
embedded in paraffin, sectioned to 9 μm, stained with hematoxilin & eosin (H&E) and mounted 
on glass slides.   
5.2.11. Micro-computed Tomography (μ-CT)
 
Samples were aligned along their axial direction and stabilized with wet gauze in a 1.5 mL 
centrifuge tube.  The tubes were clamped in the specimen holder of a vivaCT 40 system 
(SCANCO Medical AG, Basserdorf, Switzerland).  The 4 mm length of the scaffold was scanned 
at 21 mm isotropic resolution.  The radiodensity of the scaffolds (PCL, β-TCP and 
CellCeramic
TM
) 8 weeks post-implantation (bone formation) was normalized to pre-implanted 
scaffolds.   
5.2.12. Statistical Analysis 
All results were expressed as mean ± SEM.  Normality of the data was confirmed using the 
Shapiro-Wilk test (P < 0.001).  Data was analyzed with one-way analysis of variance (ANOVA), 
followed by Tukey’s minimum significant difference (MSD) post hoc test for pairwise 
comparisons of main effects.  For all comparisons, a P-value of 0.05 was considered significant. 
5.3. Results 
5.3.1. In Vivo Akermanite and Akermanite:PCL Scaffolds Acute Toxicity 
Within the first 36 hours post-implantation, sudden death was observed in animals implanted 
with akermanite scaffolds loaded with hASC and akermanite:PCL scaffolds (both stem cell 
types).  At 48 hours post-implantation, severe hypothermia and weakness were observed in the 



















Figure 22.  Calcium and phosphorus blood content 48 hours 
post-implantation (PI) in a mouse implanted with akermanite 
scaffolds loaded with hBMSC and mice implanted with PCL, 
β-TCP and CellCeramic
TM
 scaffolds 8 weeks post-








Cardiac puncture after human euthanasia revealed hemolysis and chemistry analysis of the 
hemolyzed blood revealed severe hypophosphatemia (< 0.3 mg/dL - Figure 22).  Based on this 
information, the sudden death and clinical signs observed within the first 48 hours post-
implantation in mice implanted with akermanite and akermanite:PCL scaffolds were initially 
attributed to severe phosphorous deficiency.  Animals implanted with PCL, β-TCP and 
CellCeramic
TM
 scaffolds (both stem cell types) displayed normal blood phosphorous values 8 
weeks post-implantation (11.95±1.01 – Figure 22).  
5.3.2. ICP-OES Analysis of Akermanite and Akermanite:PCL Scaffolds 
The calcium (17.82±2.17), magnesium (2.91±0.31) and silicon (2.03±0.67) contents in 
akermanite scaffolds 48 hours post-implantation were significantly higher than in 
akermanite:PCL scaffolds (4.77±1.62; 0.75±0.27; 0.10±0.01, respectively), however no 
significant differences in phosphorus (akermanite – 0.73±0.10; akermanite:PCL – 0.56±0.05) 
were observed between both scaffold types (Figure 23).   
5.3.3. XPS Analysis of Akermanite and Akermanite:PCL Scaffolds 
Figure 24 represents the percentages of calcium, magnesium, silicon and phosphorous on the 
akermanite and akermanite:PCL scaffolds surface within the first 48 hours of this study.  In 
general, no significant differences on the ionic percentage of these elements were observed on 
the surface of both scaffold types.  
5.3.4. Macroscopic Changes in PCL, β-TCP and CellCeramic
TM
 Scaffolds 8 Weeks Post-
Implantation 
 
Scaffolds harvested from nude mice 8 weeks post-implantation had grossly different color 
patterns (Figure 25A).  PCL and CellCeramic
TM






















Figure 23.  Ionic content in akermanite and akermanite:PCL scaffolds 48 hours post-










Figure 24.  Percentage of calcium, magnesium, silicon and phosphorus on the surface of 






Figure 25. Qualitative analysis of PCL, β-TCP and CellCeramic
TM
 scaffolds 8 weeks post-
implantation (A).  In B, weight gain (in mg) of the scaffolds 8 weeks post-implantation (Tukey’s 




reddish coloration compared to scaffolds preloaded with hBMSC or scaffolds implanted without 
hBMSC.  Color changes were also observed in β-TCP scaffolds preloaded with hASC and 
hBMSC or β-TCP scaffolds implanted without adult stem cells, but no noticeable differences 
between them.   
Figure 25 also depicts the weight gain of PCL, β-TCP and CellCeramic
TM
 scaffolds 8 weeks 
post-implantation (B).  In general, the scaffolds gained in average 38.47±5.2 mg in weight 8 
weeks post-implantation but no significant differences between scaffolds or adult stem cell types 
were observed. 
5.3.5. Quantitative Real-Time Polymerase Chain Reaction (QPCR) 
The OCN fold change between scaffolds preloaded with adult stem cells and scaffolds 
implanted without cells is represented in Figure 26.  According to the results, significant 
differences in the OCN expression were observed within each scaffold and adult stem cell types, 
with the exception of PCL (23.42±2.531) and CellCeramic
TM
 (32.24±2.935) preloaded with 
hASC, which were not significant different.   
Within scaffolds preloaded with hBMSC, the OCN fold change 8 weeks post-implantation 
was the highest in β-TCP (842.89±60.08) scaffolds, which was significantly higher than the 
OCN fold change observed in CellCeramic
TM
 (78.54±9.59) and PCL (5.39±2/88).  In scaffolds 
preloaded with hASC, the OCN fold change 8 weeks post-implantation was the highest in β-TCP 
(59.16±1.66) scaffolds which was significantly higher than the OCN fold change observed in 
PCL and CellCeramics
TM
 scaffolds.  Moreover, comparisons between the OCN fold change in 
scaffolds preloaded with hASC and hBMSC, indicated that after 8 weeks, hASC-scaffolds had 






































Figure 26.  Fold change expression of OCN in PCL, β-
TCP and CellCeramic
TM
 scaffolds preloaded with hASC 
and hBMSC compared to scaffolds implanted without 
adult stem cells.  *Represent significant differences 
between scaffold types loaded with the same adult stem 






5.3.6. Morphological Analysis of Implanted Scaffolds  
Routine H&E staining of PCL (a-d), β-TCP (e-h) and CellCeramic
TM
 (i-l) scaffolds 8 weeks 
post-implantation indicated high cell proliferation and a very dense collagenous matrix in all 
scaffolds tested independent of the presence or absence of hASC or hBMSC in pre-implanted 
scaffolds (Figure 26).  In general, this extracellular matrix (ECM) resembled the osteoid tissue 
formed prior to the maturation of bone tissue and its mineralization.  However, no frank bone, 
with its typical histological morphology, was observed in any of the scaffolds. 
Within the scaffolds preloaded with human adult stem cells, ECM deposition 8 weeks post-
implantation was higher in hASC-scaffolds (a, e and i) than in hBMSC-scaffolds (c, g and k).  
Additionally, between scaffold types, similar ECM deposition was observed in hASC-scaffolds 
(a, e and i), however, in hBMSC-scaffolds ECM deposition was higher in β-TCP (g) and 
CellCeramic
TM
 (k) than in PCL (c) scaffolds.   
Signs of neovascularization were observed in β-TCP scaffolds preloaded with hASC (e – 
arrowhead) and hBMSC (g – arrowhead).  One of these blood vessels contained erythrocytes 
inside (g – arrowhead), indicating that they were functionally connected to the vasculature of the 
host.  Erythrocytes were also observed in PCL scaffold preloaded with hBMSC (c – arrowhead) 
and in PCL scaffolds implanted without hASC (b – arrowhead), also suggesting migration of 
host cells through the newly formed vessels in all tested scaffolds.  
5.3.7. In Vivo Bone Density Formation 
Compared to μ-CT images taken in pre-implanted scaffolds (time point 0); noticeable 
differences in the scaffolds bone deposition 8 weeks post-implantation were observed only in 











































































































































































































































































































































































































Figure 28.  Microcomputer tomography analysis pre-implantation (time point 0) and 8 weeks 
post-implantation in PCL, β-TCP and CellCeramic
TM
 scaffolds.  Note that at time point 0, PCL 
scaffolds were not radiodense.  Moreover, quantitative analysis indicated no significant 
differences between the radiodensity of same scaffold types 8 weeks post-implantation 




radiodensity of scaffolds preloaded with adult stem cells and scaffolds implanted without cells 
were observed within each scaffold type.  The average radiodensities of PCL, β-TCP and 
CellCeramic
TM
 scaffolds 8 weeks post-implantation were, respectively, 
8844738.75±2061543.79, 5616419.54±1435693.65 and 2833596.75±1001725.68 (P > 0.05). 
Significant differences in the radiodensity of different scaffolds 8 weeks post-implantation 
were observed only between PCL scaffolds preloaded with hASC or hBMSC (average 
10023553±36397.61) or PCL scaffold implanted without hBMSC (10049286.43±4174207.85) 
which had radiodensity significantly higher than β-TCP scaffolds implanted without hASC 
(3707187.66±2276128.72) and CellCeramic
TM
 scaffolds preloaded with hASC and hBMSC or 
implanted without hBMSC (average 2337684.55±234983.60).  
5.4. Discussion 
Identification of scaffolding materials that display consistent in vivo osteogenesis 
independent of the human adult mesenchymal stem cells source is highly desirable in many bone 
tissue engineering applications (Reichert & Hutmacher, 2011).  In an experimental point of view, 
the utilization of biomaterials with similar properties under human adult mesenchymal stem cells 
stimulation could also facilitate comparisons between current in vivo protocols (Gimble et al., 
2011).  In this study, we evaluated five different biomaterials with recognized bone formation 
potential in nude mice.  However, within the initial 48 hours of this study, acute phosphorous 
depletion toxicity was associated with subcutaneous implantation of two of those bone substitute 
scaffolds (akermanite and akermanite:PCL).  In vivo comparisons of ectopic bone formation 
were carried out 8 weeks post-implantation in pure porous PCL, β-TCP and CellCeramic
TM
 
scaffolds preloaded with hASC and hBMSC.  Due to the PCL slow in vivo degradation and 
neovascularization potential, this study indicated that PCL scaffolds preloaded with hASC and 
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hBMSC displayed similar radiodensity to PCL scaffolds implanted without cells or ceramic 
scaffolds 8 weeks post-implantation.  However, even though the expression of mature osteogenic 
marker was higher in hASC-PCL than in hBMSC-PCL scaffolds, after 8 weeks, the highest OCN 
expression was observe in β-TCP scaffolds preloaded with hBMSC. 
In this study, we observed an unexpected acute dose-dependent toxicity in animals assigned 
to the akermanite and akermanite:PCL scaffolds 48 hours post-implantation.  Over the past 
years, accumulative evidences have suggested that akermanite is biocompatible and can enhance 
adhesion, proliferation and osteogenic phenotype maintenance of mature osteoblasts, hBMSC 
and hASC (Agathopoulos et al., 2005; Sun et al., 2006; Wu et al., 2006ab; Wu et al., 2007; Chen 
at al., 2010; Gu et al., 2011).  However, we could not foresee the deleterious effects of 
akermanite overexposure in the animal model selected for this study, because a femur defect 
model had been successfully proposed to study akermaninte osteogenesis in rabbits (Huang et 
al., 2009).   
Within the first 48 hours of this study, we initially suspected that the signs of phosphorus 
deficiency observed in all animals implanted with akermanite and akermanite:PCL scaffolds was 
associated with disturbance of the magnesium and phosphorous homeostasis (DiBartole 
DiBartola & Willard, 2011), because in vitro leaching of magnesium ions from akermanite 
scaffolds had been previously reported (Wu et al., 2006ab ; Gu et al., 2011) and it seems to be 
related in part, to the enhanced osteogenic potential of hASC exposed to akermanite media 
extracts (Gu et al., 2011).  However, ICP-OES and XPS analysis indicated comparable 
phosphorous content in the akermanite and akermanite:PCL scaffolds harvested 48 hours post-
implantation, which confirmed the acute phosphorous depletion observed in the murine serum.  
Phosphorus plays an essential role in cellular structure and function (DiBartola & Willard, 2011).  
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As a constituent of structural phospholipids in cell membranes and hydroxyapatite in bone, 
phosphorus also is an integral component of nucleic acids and phosphoproteins involved in 
mitochondrial oxidative phosphorylation.  Consequently, severe hypophosphatemia can cause 
many detrimental effects (DiBartola & Willard, 2011).  As observed in this study, 
hypophosphatemia associated with akermanite depletion of phosphorous, lead to hemolysis due 
to the increased erythrocyte fragility associated with the decreased concentration of ATP in the 
blood (DiBartola & Willard, 2011).  Moreover, the neuromuscular signs observed 48 hours post-
implantation were also associated with the akermanite scaffolds, because decreased phosphate 
can impair central nervous system glucose use and ATP production, leading to metabolic 
encephalopathy, which can be fatal (DiBartola & Willard, 2011).  Therefore, the increased 
ability that akermanite has to form apatite-like layers at a physiological fluid interface (Sun et al., 
2006; Liu et al., 2008; Gu et al., 2011) seems to have played a role in the acute toxicity 
associated with the akermanite scaffolds used in this study.  Further studies are needed to address 
the akermanite dose-dependent toxicity in murine models for akermanite-assisted bone 
regeneration.  
Evaluation of the in vivo ectopic bone formation of PCL, β-TCP and CellCeramic
TM
 
scaffolds revealed remarkable similarities between the bone substitute scaffolds independent of 
the presence of hASC or hBMSC 8 weeks post-implantation.  According to the results, all 
scaffolds tested displayed similar weight gains after 8 weeks; however μ-CT images revealed 
increased bone formation in PCL and β-TCP scaffolds.  Further morphologic analysis, revealed a 
very dense collagenous matrix resembling osteoid tissue in all scaffolds independent of the 
presence of hASC and hBMSC, however, no bone-like tissue, with its typical histological 
morphology, was observed in any of the scaffolds.   
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Osteogenesis is known to be regulated by bone morphogenic proteins (BMPs) which have 
been reported to stimulate the transcription factor core binding factor alpha1 (Cbfa1) by 
activating osteoblast-specific genes such as OCN through the binding to the osteoblast-specific 
cis-acting element 2 (OSE2) in the promoter region of these genes (Liu et al., 2008; Gu et al., 
2011).  In this study, OCN was also used to asses mature osteogenic differentiation of the 
scaffolds preloaded with hASC and hBMSC.  Even though the OCN expression was higher in 
hASC-PCL than in hBMSC-PCL scaffolds, after 8 weeks, the highest OCN expression was 
observe in β-TCP scaffolds preloaded with hBMSC.  β-TCP is known to stimulate adult stem 
cells osteogenesis (Sun et al., 2006; Liu et al., 2008; Huang et al., 2009).  Therefore, the results 
presented in this study can be also used to support the osteoinductive potential of β-TCP in bone 
tissue engineering applications.   
The similarities observed in this study between PCL and other two bone substitute scaffolds, 
in terms of weight gain and radiodensity, might had been associated with the fast in vivo 
degradation potential of β-TCP and CellCeramic
TM
 scaffolds (Bouler et al., 2000; Gaalen et al., 
2008; Liu et al., 2008; Marino et al., 2010).  Synthetic apatites degrade overtime through 
physiochemical dissolution and phagocytosis (Bouler et al., 2000; Gaalen et al., 2008; Chen et 
al., 2010).  PCL has slow degradation in vivo (Leong et al., 2006; Gaalen et al., 2008; Zhang et 
al., 2009; Fabbri et al., 2010), therefore, the comparable weight gains and the calcified ECM 
deposition observed between the scaffolds after 8 weeks could have been the result the stability 
of the PCL scaffolds.   
In this study, scaffolds implanted without hASC and hBMSC had weight gains, 
radiodensities and morphological features similar the observed in scaffolds preloaded with either 
adult stem cell type.  As observed in the histological sections, neovascularization could had 
146 
 
offered an avenue for host cell migration, adhesion and proliferation in the implanted scaffolds.  
Further investigations to assess the presence of human sex chromosomes in scaffolds implanted 
without cells would be beneficial to determine the origin of the cells adhered to the scaffolds 8 
weeks post-implantation, as previously described (Levi et al., 2010).  
As a conclusion, we observed in this study that PCL scaffolds had weight gain, radiodensity 
and morphological features similar to the observed in β-TCP and CellCeramic
TM
, independent of 
the presence or the source of the adult stem cells.  However, increased OCN expression was 
observed in β-TCP scaffolds preloaded to hBMSC.  Host cell migration might had played a role 
in the high cell proliferation and matrix deposition observed in scaffolds implanted without cells, 
but further investigations are needed to identify the origin of those cells.  Finally, the sudden 
death observed in nude mice implanted with akermanite and akermanite:PCl within the first 48 
hours of this study was associated to acute phosphorous depletion from the blood.  Further 
investigations are also needed to determine an optimal akermanite dose for murine models.  
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Chapter 6. Conclusions 
The development of porous materials useful as scaffolds for the sustained 3D growth of 
hASC is of particular interest to facilitate healing after musculoskeletal injuries.  While current 
scaffold materials facilitate the attachment of hASC by providing an interconnected pore 
structure to support cell migration, proliferation, differentiation and in some cases formation of 
blood vessels
40,47
, the major limitations of pure ceramic scaffolds used today are their relatively 
poor mechanical properties and brittle behavior.  As a consequence, the use of 
bioactive/bioabsorbable ceramics and bioabsorbable polymeric fiber reinforcement in the same 
composite structure are being explored as an alternative to address the mechanical limitations of 
pure ceramic scaffolds.  To date, a clear trend towards the use of composite scaffolds can already 
be observed in current hASC-scaffolds bone tissue engineering models.   
Of the bioactive ceramic materials current used in hASC bone tissue engineering, akermanite 
(Ca2MgSi2O7), is the only biomaterial used entirely in its pure form.  Compared to β-TCP and 
HA, akermanite scaffolds are believed to have a stable degradation rate and superior bone 
deposition.  Moreover, the enhanced recruitment and osteogenic commitment of progenitor cells 
exposed to akermanite scaffolds, seems to be associated with the cells affinity for the Ca, Mg, 
and Si ions that makeup the akermanite scaffold backbone.  Due to the enhanced biological and 
mechanical properties of akermanite in bone tissue engineering applications combined with 
hASC, we proposed in a series of hypotheses driven experiments the development of a novel 
composite scaffold suitable for hASC-assisted bone engineering.   
In our first study, we characterized the scaffold properties (porosity, pore size, compressive 
strength and degradation) and hASC viability, attachment, proliferation and osteogenic 
differentiation to akermanite in the presence of PCL.  As one of the most versatile synthetic 
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polymers currently used, PCL has been also proposed as composite scaffold in many hASC bone 
engineering studies.  In our study, we determined that the combined mechanical, biological and 
osteogenic properties of 75:25 akermanite:PCL composite scaffolds should be further evaluated 
for bone repair applications combined with hASC.   
As a result, in the next two in vitro studies, we characterized the osteogenic potential of 
hASC loaded to 75:25 akermanite:PCL scaffolds cultured in growth (control) and osteogenic 
media for 21 days; and we assessed the metabolic activity and osteogenesis of hASC loaded to 
75:25 akermanite:PCL scaffolds in post-thawed scaffolds frozen at 5 different cooling rates in a 
PVP-serum free medium.  According with these results, we observed that the metabolic activity 
and cell proliferation of hASC loaded to 75:25 akermanite:PCL scaffolds and cultured in growth 
(control) or osteogenic media proportionally decreased after 21 days, but were inversely 
proportional to the calcium deposition and expression of mature osteogenic marker (OCN) 
observed in 75:25 akermanite:PCL scaffolds cultured in osteogenic medium.  For scaffolds 
frozen at different cooling rates, our results demonstrated that 75:25 akermanite:PCL scaffolds 
loaded with hASC can be cryopreserved with 10% PVP in serum-free medium.  Moreover, after 
10 days of culture, optimal hASC metabolic activity and osteogenesis were observed in scaffolds 
initially frozen at 40ᵒC/min.  As a conclusion, the results of these two additional in vitro 
experiments indicated that hASC loaded to 75:25 akermanite:PCL scaffolds had enhanced 
bioactivity, which led us to further evaluate the biocompatibility of akermanite:PCL scaffolds in 
vivo using an immunodeficient murine model for ectopic bone formation.   
Unexpectedly, within the first 48 hours of this in vivo experiment, we observed sudden death 
of all mice assigned to the akermanite and akermanite:PCL scaffolds.  Based on the literature and 
the composition of the akermanite and akermanite:PCL scaffolds, we further evaluated the cause 
152 
 
of the mortality observed in this study.  Results indicated comparable phosphorous content in all 
akermanite and akermanite:PCL scaffolds harvested 48 hours post-implantation.  The results 
combined with the acute phosphorous depletion observed in the murine serum, confirmed the 
acute toxicity associated with akermanite-based scaffolds.  
Over the past years, accumulative evidences have suggested that akermanite is biocompatible 
and can enhance adhesion, proliferation and osteogenic phenotype maintenance of 
adult/osteoprogenitor stem cells.  However, we could not foresee the deleterious effects of 
akermanite overexposure in the animal model selected for this study, because a rabbit model for 
femur defect had been successfully proposed to study akermaninte osteogenesis.  Therefore, the 
conclusion of this study is that further studies are needed to address the akermanite dose-
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